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Abstract
Clinical effectiveness and cost-effectiveness of body
psychotherapy in the treatment of negative symptoms of
schizophrenia: a multicentre randomised controlled trial
Stefan Priebe,1* Mark Savill,1 Til Wykes,2 Richard Bentall,3
Christoph Lauber,4 Ulrich Reininghaus,2,5 Paul McCrone,6
Iris Mosweu,6 Stephen Bremner,7 Sandra Eldridge8
and Frank Röhricht1 on behalf of the NESS team
1Unit for Social and Community Psychiatry, World Health Organization Collaborative Centre for
Mental Health Services Development, Queen Mary University of London, London, UK
2Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
3Department of Psychiatry, University of Liverpool, Liverpool, UK
4Services Psychiatriques Jura bernois, Bienne-Seeland, Bellelay, Switzerland
5Department of Psychiatry and Psychology, School for Mental Health and Neuroscience,
Maastricht University, Maastricht, The Netherlands
6Centre for the Economics of Mental and Physical Health, Institute of Psychiatry, Psychology and
Neuroscience, King’s College London, London, UK
7Division of Primary Care and Public Health, Brighton and Sussex Medical School, Brighton, UK
8Centre for Primary Care and Public Health, Queen Mary University of London, London, UK
*Corresponding author s.priebe@qmul.ac.uk
Background: The negative symptoms of schizophrenia significantly impact on quality of life and social
functioning, and current treatment options are limited. In this study the clinical effectiveness and
cost-effectiveness of group body psychotherapy as a treatment for negative symptoms were compared
with an active control.
Design: A parallel-arm, multisite randomised controlled trial. Randomisation was conducted independently
of the research team, using a 1 : 1 computer-generated sequence. Assessors and statisticians were blinded
to treatment allocation. Analysis was conducted following the intention-to-treat principle. In the
cost-effectiveness analysis, a health and social care perspective was adopted.
Participants: Eligibility criteria: age 18–65 years; diagnosis of schizophrenia with symptoms present at
> 6 months; score of ≥ 18 on Positive and Negative Syndrome Scale (PANSS) negative symptoms subscale;
no change in medication type in past 6 weeks; willingness to participate; ability to give informed consent;
and community outpatient. Exclusion criteria: inability to participate in the groups and insufficient
command of English.
Settings: Participants were recruited from NHS mental health community services in five different Trusts.
All groups took place in local community spaces.
Interventions: Control intervention: a 10-week, 90-minute, 20-session group beginners’ Pilates class, run
by a qualified Pilates instructor. Treatment intervention: a 10-week, 90-minute, 20-session manualised
group body psychotherapy group, run by a qualified dance movement psychotherapist.
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Outcomes: The primary outcome was the PANSS negative symptoms subscale score at end of treatment.
Secondary outcomes included measures of psychopathology, functional, social, service use and treatment
satisfaction outcomes, both at treatment end and at 6-month follow-up.
Results: A total of 275 participants were randomised (140 body psychotherapy group, 135 Pilates group).
At the end of treatment, 264 participants were assessed (137 body psychotherapy group, 127 Pilates
group). The adjusted difference in means of the PANSS negative subscale at the end of treatment was
0.03 [95% confidence interval (CI) –1.11 to 1.17], showing no advantage of the intervention. In the
secondary outcomes, the mean difference in the Clinical Assessment Interview for negative symptoms
expression subscale at the end of treatment was 0.62 (95% CI –1.23 to 0.00), and in extrapyramidal
movement disorder symptoms –0.65 (95% CI –1.13 to –0.16) at the end of treatment and –0.58 (95% CI
–1.07 to –0.09) at 6 months’ follow-up, showing a small significant advantage of body psychotherapy.
No serious adverse events related to the interventions were reported. The total costs of the intervention were
comparable with the control, with no clear evidence of cost-effectiveness for either condition.
Limitations: Owing to the absence of a treatment-as-usual arm, it is difficult to determine whether or not
both arms are an improvement over routine care.
Conclusions: In comparison with an active control, group body psychotherapy does not have a clinically
relevant beneficial effect in the treatment of patients with negative symptoms of schizophrenia. These
findings conflict with the review that led to the current National Institute for Health and Care Excellence
guidelines suggesting that arts therapies may be an effective treatment for negative symptoms.
Future work: Determining whether or not this lack of effectiveness extends to all types of art therapies
would be informative.
Trial registration: Current Controlled Trials ISRCTN842165587.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 20, No. 11.
See the NIHR Journals Library website for further project information.
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Plain English summary
Symptoms of schizophrenia, such as reduced emotions and lack of drive, can reduce a person’s qualityof life. At present, there are few treatment options that have been found to help. Arts therapies
(which involve different, more creative ways to help people communicate than just talking) may be helpful,
but more evidence is needed.
One form of art therapy is body psychotherapy, which uses movement and the body as a form of
treatment. In a recent small study, body psychotherapy was found to reduce symptoms, but it is not clear
if it is the group activity or the therapy itself that caused the improvement, or if the improvement would
still occur if the treatment was conducted at different sites by different therapists.
In this study, 275 people were randomised to take part in a 20-session body psychotherapy group or a
20-session Pilates class. Symptoms, the cost of health services used and measurements of well-being were
taken before the first group session, after the last session and then again 6 months later. The
measurements from the participants who were offered the body psychotherapy group were then
compared with those who were offered the Pilates class.
In both groups only very small improvements in symptoms were found, which means that the body
psychotherapy group did not improve symptoms more than Pilates. These findings appear to contradict
the current guidelines, which suggest that art therapies may be helpful in addressing a lack of drive and
reduced emotions.
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Scientific summary
Background
The negative symptoms of schizophrenia refer to expressive deficits, such as impoverished speech and
blunted affect, and experiential/pleasure deficits, such as anhedonia, avolition and asociality. These
negative symptoms have been found to be largely resistant to antipsychotic medication and conventional
psychotherapeutic interventions, and significantly impact on quality of life and social functioning. There is
some evidence to suggest that arts therapies could be effective in the treatment of these symptoms;
however, the current data are limited and full-scale trials are required.
In a review by the National Institute for Health and Care Excellence (NICE), arts therapies – which is a label
covering all creative therapies, such as music therapy, art therapy, body psychotherapy (BPT), dance
movement psychotherapy and drama therapy – were the only type of intervention found to demonstrate
consistent efficacy in the amelioration of negative symptoms. However, given that the findings were based
on only six small-scale studies, the recommendations for further research recognised the need for larger
trials. In addition, it was recommended that trials include an active control group in order to control for
any non-specific effects of taking part in group activities.
The aim of this trial is to assess the clinical effectiveness and cost-effectiveness of a manualised form of
group BPT that was designed to treat the negative symptoms of schizophrenia in outpatients, comparing
outcomes with those from outpatients attending Pilates classes. Pilates is a type of structured physical
fitness programme involving stretching and controlled movement, which will control for the effects of
therapist attention and group-structured physical activity. In comparing BPT with a physically active control,
the aim of the trial was to evaluate the specific components of BPT, which includes the focus on body
experience at a cognitive and emotional level, the facilitation of emotional group interactions and the link
between movement and emotion.
Objectives
The objectives were to:
1. test the effectiveness of a manualised group BPT intervention in reducing negative symptoms of
schizophrenia compared with an active control
2. test the effectiveness of a manualised group BPT intervention in general psychopathology, quality of
life, daily activities, objective social situation and treatment satisfaction in participants who were
experiencing negative symptoms of schizophrenia compared with an active control
3. test whether or not any effects on primary and secondary outcomes are maintained at 6 months’
follow-up
4. assess the cost impact, cost-effectiveness and cost–utility of BPT.
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Method
The study was a two-arm, parallel-group, multisite randomised controlled trial (RCT). Patients with
schizophrenia [International Classification of Diseases, Tenth Edition (ICD-10) codes F20.0–F20.9]
experiencing at least moderate levels of negative symptoms [score of ≥ 18 on the Positive And Negative
Syndrome Scale (PANSS) negative subscale] were randomised into a 20-session (10-week) BPT group, or a
20-session (10-week) Pilates class. Randomisation was conducted by a statistician from the Clinical Trials
Unit through a computer-generated sequence. Participants were randomly allocated, with equal
probability, to the intervention or control group, stratified by study centre, in batches using randomly
permuted blocks of 4 and 6, starting each batch at the start of a new block in order to preserve balance.
Assessors and statisticians were blinded to treatment allocation until the analysis plan was signed off.
Analysis was conducted following intention-to-treat principles.
Participants
Participants were recruited from the UK NHS mental health community services in five different Trusts. The
eligibility criteria included ages 18–65 years; ICD-10 diagnosis of schizophrenia, with symptoms present for
at least 6 months; score of ≥ 18 on PANSS negative symptoms subscale; no change in medication type in
the past 6 weeks; willingness to participate; ability to give informed consent; and community outpatient.
The exclusion criteria included inability to participate in the groups because of physical disability or
condition and insufficient command of English. All groups took place in local community spaces.
Procedures
Potentially eligible participants were approached by their clinicians for their consent to be contacted by a
researcher. If they agreed, the researcher arranged a meeting during which a detailed explanation of the
study was provided, and, presuming that they were interested in taking part, informed consent was obtained.
An eligibility assessment using the PANSS scale was then conducted to ascertain whether or not they had a
rating of at least 18 on the negative symptoms subscale, in accordance with the inclusion criterion. Once
approximately 16 eligible participants at each site were recruited, a full baseline assessment – which included
a second PANSS assessment – was undertaken 1 month prior to the group start date. The assessments were
typically conducted in the participants’ homes or at their local community mental health team base.
On completion of the groups, the researchers contacted the participants again for the end-of-treatment
assessment, which included all of the structured interviews and questionnaires obtained in the baseline
assessment, in addition to the Client Satisfaction Questionnaire (CSQ) which was used to measure the
participants’ satisfaction with treatment. Six months after intervention completion, patients were contacted
a final time to arrange the follow-up assessment, which, again, included all of the interviews and
questionnaires of the baseline assessment.
The treatment under investigation was BPT, as outlined in an updated version of the manual used in the
2006 exploratory trial. Both BPT and the Pilates groups were delivered twice per week on non-consecutive
days for 10 weeks, with each session lasting 90 minutes. A maximum of 10 participants were assigned to
each group or class. To limit the impact of any one body psychotherapist or Pilates instructor on outcomes,
each one was permitted to run a maximum of two groups.
The BPT group was facilitated by an Association of Dance Movement Psychotherapy (ADMP) accredited
therapist, who had attended an additional 2-day training course in delivering the intervention in its
manualised form. In each group, the therapist was supported by a volunteer as cofacilitator. Each therapist
received a minimum of three 90-minute supervision sessions held by a senior therapist for each group,
either in person or via a videoconference.
SCIENTIFIC SUMMARY
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Each of the 20 sessions comprised five discrete sections. The first was the opening circle, which is used to
describe feelings and energy levels; the second was a warm-up section, for which the participants stand in
a circle and warm up using different body parts and movements; the third was a structured task section
with exercises, such as mirroring each other’s movements and creating body image sculpture in partners;
the fourth consisted of creative movements, with exercises such as creating group sculptures and reflecting
on perceptions and emotions; and finally, the fifth was a closing circle, which was used to reflect on the
group experience and to refocus on the self with body-orientated exercises.
The Pilates classes were held in the same venues as the BPT groups. All classes were facilitated by a
Register of Exercise Professionals (REPS) level 3-qualified Pilates instructor, and assisted by a cofacilitator.
Prior to the classes starting, a brief training session was arranged between the instructor and an
experienced clinician.
Outcomes
The primary outcome was the PANSS negative symptoms subscale score, which was assessed at the end of
treatment. Secondary outcomes included the PANSS negative subscale score at 6 months post treatment,
in addition to general psychopathology and positive symptoms (PANSS), subjective quality of life
(Manchester Short Assessment of Quality of Life; MANSA), level of activity (items from the Time Use
Survey; TUS), objective social situation (SIX), extrapyramidal symptoms resulting from antipsychotic
medication (Simpson–Angus Scale; SAS), emotional experience and expression (Clinical Assessment
Interview for Negative Symptoms; CAINS), depression (Calgary Depression Scale) and social contacts (Social
Network Scale; SNS), measured both at end of treatment and at 6 months’ follow-up. Satisfaction of
treatment was measured at the end of the treatment phase (Client Satisfaction Questionnaire; CSQ). In
addition, cost impact, cost-effectiveness and cost–utility were assessed using the European Quality of Life-5
Dimensions (EQ-5D) and the Client Service Receipt Inventory (CSRI).
Statistical methods
A 20% reduction in the PANSS score was used as an indicator of clinically significant improvement, which
would be a difference of approximately 3 points, given the eligibility criteria. To detect this difference with
a standard deviation (SD) of 5, with 90% power for 5% significance, 58 patients were required in each
arm. To allow for clustering by group, an intraclass correlation coefficient (ICC) for treatment group of 0.1,
and seven patients per group with analysable data at the end of treatment, gives an inflation factor of 1.6,
meaning that 93 participants in each arm were required. At 6 months we anticipated a loss to follow-up
of 31%, so recruiting 256 participants would leave 88 per arm at 6 months, and 91% power to detect a
difference of 3 points at this time point.
The primary analysis was of available cases of the PANSS negative subscale at end of treatment, following
intention-to-treat principles. We used a mixed-effects model, fitted by restricted maximum likelihood with
fixed effects for the intervention, baseline PANSS negative subscale scores, and centre (because it was used
to stratify the randomisation), and random effects for therapy groups to allow for clustering by group.
Secondary outcomes were analysed using the same approach. To evaluate the impact of missing
data, multiple imputation of the data set was performed and the analysis was replicated. A simple
complier-average causal effect analysis (CACE) was completed. In this analysis, compliance was defined as
attending at least five sessions, following the results of a recent study that evaluated the effectiveness of
BPT for chronic depression. Planned subgroup analyses examining whether or not there were differences in
response between those with higher negative symptoms at baseline and a longer duration of illness were
also conducted. All analyses were completed using Stata version 12 (StataCorp LP, College Station, TX, USA).
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Results
In total, 275 participants were randomised: 140 to the BPT group and 135 to the Pilates group. Each
group comprised between 7 and 10 participants. Attendance was relatively high in both groups; however,
participants attended significantly more sessions in the BPT arm than in Pilates group [BPT median= 11,
interquartile range (IQR)= 5–17; Pilates median= 8, IQR= 1–15; p= 0.01]. In the BPT arm, 106 participants
(75.7%) attended at least 5 of the 20 sessions, thus fulfilling the minimum attendance threshold required
to be defined as a treatment complier in the CACE analysis.
In the primary outcome, no significant difference between the experimental and control condition was detected
[adjusted difference in the means= 0.03, 95% confidence interval (CI) –1.11 to 1.17; p= 0.959, model-based
ICC= 0.099 after controlling for baseline scores, study centre and therapy group]. In the secondary
outcomes at the end of treatment, a significant mean difference reduction in the SAS (–0.65, 95% CI
–1.13 to –0.16; p= 0.009, ICC< 0.001) and the CAINS expression subscale (–0.62, 95% CI –1.23 to 0.00;
p= 0.049, ICC= 0.022) was detected in favour of the BPT arm in comparison with the Pilates group at the
end of treatment. No other significant differences were found in the secondary outcomes at this stage.
At the 6-month follow-up, a significant mean difference in the SAS was detected (–0.50, 95% CI –0.97 to
–0.07; p= 0.028, ICC< 0.001); however, no other differences were detected.
In the CACE analysis, a significant difference was found in the SAS at end of treatment (–0.82, 95% CI
–1.51 to –0.12); however, no other differences were detected, including in the primary outcome of negative
symptoms. No significant differences in negative symptoms were detected in the subgroup analysis, which
compared those with high and low negative symptoms, and long and short duration of illness. There were
no serious adverse events related to the intervention.
The total mean costs per participant in the BPT over the whole follow-up period were £2297 (SD= £2835)
in comparison with £2442 (SD= £3278) for Pilates. After adjusting for baseline, the total costs were slightly
lower for BPT; however, the difference was non-significant (£25; bootstrapped 95% CI –£671 to £721).
No significant differences were detected in the sensitivity analysis, for which the costs of Pilates were
changed to zero (–£55, 95% CI –£630 to £706). No significant differences were detected in quality-adjusted
life-years (QALYs) between BPT and Pilates (adjusted difference in means= 0.01; 95% CI –0.02 to 0.04).
At £20,000 per QALY, it was found that there is approximately a 65% likelihood that BPT is a more
cost-effective option than Pilates.
Conclusions
No significant differences between BPT and Pilates were detected in the PANSS negative symptoms
subscale, both at the end of treatment and 6 months later. A statistically significant improvement in the
BPT group in comparison with the Pilates group was detected in the CAINS expression subscale at the end
of treatment, and, in movement disorder symptoms, both at end of treatment and 6 months later.
However, the small effect sizes mean these are unlikely to reflect relevant clinical benefits. There was no
significant difference on any other outcome. Given the results and the high statistical power, these
findings support the conclusion that BPT is not an effective treatment for patients with negative symptoms
of schizophrenia compared with Pilates as an active control.
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Implications for health care
In comparison with an active control, group BPT does not have a clinically relevant beneficial effect in the
treatment of patients with negative symptoms of schizophrenia. These results are consistent with an earlier
RCT [Multicenter evaluation of Art Therapy in Schizophrenia: Systematic Evaluation (MATISSE)] evaluating
the effectiveness of art therapy as a treatment for schizophrenia and, together, contradict current NICE
guidelines, which suggest that arts therapies are an effective treatment for negative symptoms.
Trial registration
This trial is registered as ISRCTN842165587.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Schizophrenia and negative symptoms
Schizophrenia is a severely disabling mental health disorder that affects approximately 0.7% of the
population.1 The main symptoms are commonly characterised into ‘positive’ symptoms, which include
hallucinations, disordered thinking and delusions, and ‘negative’ symptoms, which refer to deficits in
emotional experience and expression. Specific symptoms relating to emotional expression include blunted
affect and alogia (impoverished speech), whereas deficits in emotional experience can include asociality,
anhedonia (inability to anticipate or experience pleasure) and amotivation.2
Negative symptoms have been found to be highly detrimental to social outcomes, quality of life and
functioning,3,4 and so are important targets for treatment. However, despite developments in both
antipsychotic medication and psychological treatments, the effectiveness of most treatments on negative
symptoms has been found to be limited.5 This being the case, the negative symptoms are currently
recognised as an unmet therapeutic need in a large proportion of cases.5
Schizophrenia and arts therapies
‘Arts therapies’ is an umbrella term for a range of different therapies, which include music therapy, art
therapy, body psychotherapy (BPT), dance movement psychotherapy and drama therapy. Common to all of
them is that they have a central non-verbal component, with the focus on utilising creative activities to
achieve psychological change. In a review on treatment strategies in schizophrenia by the National Institute
for Health and Care Excellence (NICE), arts therapies were found to be the only type of treatment to
demonstrate clear, consistent improvement in negative symptoms;6,7 however, the sample size for the
meta-analysis was small (six trials, n= 382), leading to the suggestion that the evidence base should be
increased with more large-scale trials of arts therapies. Furthermore, none of the studies compared the
intervention with an active control, so it remains unclear whether it is the specific effects of the
psychotherapeutic component of arts therapies or the non-specific effects of regular group activity that are
driving the changes. Finally, no studies evaluating evidence on the cost-effectiveness of such interventions
were identified. Consequently, the research recommendations suggested that further trials should be
conducted to test the clinical effectiveness and cost-effectiveness of arts therapies for patients with
schizophrenia, that such trials should be sufficiently powered and that they should use an active control.
Since the recommendations were published, a full-scale, multicentre randomised controlled trial (RCT)
evaluating the effectiveness of art therapy has been completed [Multicenter evaluation of Art Therapy in
Schizophrenia: Systematic Evaluation (MATISSE)].8 In this study, no significant improvements in either
negative symptoms or any of the secondary outcomes were found in the art therapy group, relative to
either the active control group or standard care. The MATISSE trial8 was designed as a pragmatic trial with
the aim of testing the impact of group art therapy delivered in current clinical practice, meaning that one
specific model of therapy was not evaluated. Consequently, the type of treatment provided was not
consistently applied, which has been criticised by some art therapists, who have suggested that what was
evaluated is not what is routinely delivered in the UK.9,10 In response to this critique, the MATISSE study
team have since published a more comprehensive description of the therapy delivered,11 which contends
that such a method of implementation is consistent with the principles of pragmatic trials. Regardless, new
trials of arts therapies that implement a standardised therapy, recognised as appropriate for the patient
group beforehand, would be a significant advance in the evidence base.
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Following the MATISSE trial,8 a second important issue is that it is not currently clear whether any lack of
effectiveness in the treatment of negative symptoms is specific to the art therapy that was delivered in this
context or endemic to all ‘arts therapies’ as a whole. In recognition of this, the MATISSE8 trial research
recommendations suggest that ‘Data from exploratory trials of other creative therapies, including music
therapy and body movement therapy, have shown promising results and randomised trials examining the
clinical effectiveness and cost-effectiveness of offering these interventions to people with schizophrenia
should be conducted’ (p. xii).8 Therefore, research on other arts therapies modalities might help to assess
whether the lack of efficacy of art therapy on negative symptoms is particular to this type of psychotherapy
or is indicative of arts therapies as a whole.
Body psychotherapy and schizophrenia
Of the six studies included in the NICE review,6 three studies12–14 evaluated the effectiveness of music
therapy, two studies15,16 evaluated the effectiveness of art therapy and one study17 evaluated the
effectiveness of body-orientated psychotherapy. The BPT trial was an exploratory RCT, which tested a
manualised form of the intervention in outpatients with persistent negative symptoms of schizophrenia.
Compared with a control group receiving supportive counselling, patients in the experimental group
showed a significant improvement in negative symptoms. The effect size was large, and maintained at
4 months’ follow-up. The major limitations of the study were that it was a small exploratory trial, based
at one site and with only one body psychotherapist, and that the control condition was supportive
counselling, which turned out to be unattractive to patients. In addition, the non-specific effects of physical
activity could not be controlled for and the study was insufficient in size to evaluate cost-effectiveness.
Following these findings, an open uncontrolled trial of manualised BPT18 was conducted by the same
authors, but different therapists, which yielded similar results; however, no other rigorous trials on BPT or a
similar method have been identified in a recent Cochrane review update.19
Regarding earlier trials on BPT and schizophrenia, which are not included in the NICE review, the earliest
trial was published in 196520 and found significant improvements of affective contact and general
functioning. Since then, further investigations of body-orientated psychotherapy have suggested some
improvements in a range of outcomes, including some indicators of negative symptoms.21–23 However,
all of these studies, which were exclusively conducted before 1980, have serious methodological
shortcomings, such as small sample sizes, vaguely defined outcome criteria, no systematic assessment of
psychopathology, no recording of medication, no intention-to-treat analysis and a poorly defined
description of the intervention under investigation. Overall, there is current and historic evidence to
suggest that BPT might be effective in the treatment of schizophrenia; however, further evidence from
rigorous, full-scale trials is required.
Theoretical basis for body psychotherapy as a treatment
for schizophrenia
Body-orientated psychotherapies have a long tradition in psychiatry and have existed in many different
forms, which can lead the field to appear somewhat heterogeneous. In a review of the field,24 Röhricht
identified the three main historical roots of BPT as neo-Reichian psychotherapies, concentrative movement
therapy and dance movement psychotherapies, but suggested that, in practice, a substantial degree of
overlap exists between the different schools of thought. In the review it was proposed that the immediacy
of bodily experience may be an important tool in reality testing and developing a sense of inter-relational
embodiment, and so therefore may offer unique benefits in working with those with psychosis.
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Three different models of mechanism have been proposed in support of the hypothesis that BPT may be
an effective treatment for schizophrenia and negative symptoms. Regarding the first,25 one of the core
features of negative symptoms relates specifically to diminished emotional expression. Consequently,
patients can often experience significant barriers when engaging in conventional psychotherapies in which
verbalising emotions and cognitions may be a core component of the treatment. BPT offers an alternative,
non-verbal model of facilitating emotional interactions, which some patients might find preferable or
more accessible.
The second model of mechanism relates to the link between movement and emotion. Patients with
schizophrenia often experience significant deficits in emotional experience, and can display a range of
motor abnormalities.25,26 Central to BPT is the link between movement and emotional experience,
encouraging the patient to focus on the immediacy of experiences, which may result in, or from,
movement. In doing so, this further opens greater opportunities for reality testing, and can reinforce the
idea that the body can be a source of creativity and pleasure. This may be significant when working with
patients who report significant deficits in anticipating pleasure.27 This emotional learning can be further
enhanced by the group experience, when patients can observe and imitate expressive movements in
other patients.
The third model of mechanism is related to how BPT can potentially enhance body and self-experience.
Patients with schizophrenia can frequently have misperceptions regarding their body, and altered body
experience in the form of disturbed body perception and body image.28,29 As such, a therapeutic method
that places particular emphasis on the patients’ perceptions and experiences of their body, and its
movements may be an effective way of addressing these symptoms.
Features of the body psychotherapy treatment
Presuming that the therapy is effective, there are a number of potential advantages, inherent in BPT,
which may make it an attractive option to health providers. First, as a group-based method, BPT is
relatively inexpensive. In addition, it can be administered by existing clinicians, employed by the UK NHS,
after minimal additional training, and the groups can be held in standard therapy spaces. Second,
BPT can be flexibly combined with other treatment methods, including all pharmacological interventions.
Third, given that the focus of treatment is non-verbal in nature, centring instead on body movement and
creativity, the treatment may be more accessible to patients who present with negative symptoms, such
as alogia. Lastly, because BPT is so distinct from conventional treatment methods, it may appeal to patients
who struggle to engage in other forms of treatment. The latter point is underlined by findings of a
qualitative evaluation of the exploratory trial,18 in which patients fed back positively about both its focus
and methods.
Effects of physical activity in schizophrenia
As previously highlighted, one of the limitations in the earlier exploratory trial17 was that the control
condition was group-supportive counselling, which meant that the non-specific effects of physical activity
could not be controlled for. In a recent Cochrane review,30 there is some evidence to suggest that exercise
may be at least partially effective in the treatment of negative symptoms, whereas others31 have examined
possible neurological effects of increased physical activity in schizophrenia. This being the case, at present
it is not clear whether or not the psychotherapeutic content of the sessions provide any additional benefit
over and above what may be achieved from regular activity.
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In order to examine the specific effects of this particular treatment, BPT was compared with a structured
physically active control group, namely a beginner’s Pilates class. Pilates was chosen as the active control
condition as it can be delivered in a structured format by a trained instructor, does not foster group interaction
and does not include elements that are broadly equivalent to mindfulness like other low-intensity activities,
such as yoga or t’ai chi. By comparing BPT with an active control, this investigation will allow for the evaluation
of the specific effects of the therapy. In the event that no significant difference between the treatment
conditions is found, disentangling whether they are both equally effective, as opposed to neither being
effective, may be impossible to achieve in the absence of a treatment-as-usual arm. However, in a small trial32
examining the effectiveness of yoga therapy, in comparison with an active control condition, a significant
improvement in negative symptoms was found, which suggests the approach adopted in this trial is a
feasible one.
Aims and objectives
Following the recommendations of NICE,6 we conducted a multisite, RCT to compare the effectiveness of
BPT with a physically active control condition, namely Pilates. In controlling for the effects of therapist
attention and regular structured physical activity, the specific components of the treatment under
investigation were the focus on body experience at a cognitive and emotional level, the facilitation of
emotional group interactions, and the link between movement and emotion. The Pilates group controlled
for the effect of therapist attention and structured physical activity as alternative explanations of the effect
discovered in the exploratory trial.
The aims of this trial were to:
1. test the effectiveness of a manualised group BPT intervention in reducing negative symptoms of
schizophrenia compared with an active control
2. test the effectiveness of a manualised group BPT intervention in general psychopathology, quality of
life, daily activities, objective social situation and treatment satisfaction in patients experiencing negative
symptoms of schizophrenia compared with an active control
3. test whether or not any effects on primary and secondary outcomes are maintained at 6 months’
follow-up
4. assess the cost impact, cost-effectiveness and cost–utility of BPT.
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Chapter 2 Methods
Design
The study is an assessor-blinded, parallel-arm RCT. A detailed study design description is available in the
published protocol.13 Prior to recruitment, the study was registered through the International Standard
Randomised Controlled Trial Number (ISRCTN) system (ISRCTN84216587).
Amendments to the protocol
Through the implementation of the project, five amendments were made, all approved by the Research Ethics
Committee (REC) and the study sponsors prior to implementation. The changes included are listed below.
Amendment 1
On the advice of the Trial Steering Committee (TSC) an additional inclusion criterion was added, specifying
that the type of antipsychotic medication prescribed to participants should not change for at least 6 weeks
prior to baseline assessment, although a change in dosage is acceptable. In addition, the Calgary
Depression Scale33 was added to the case report file (CRF) battery, again on the suggestion of the TSC.
During the set-up phase, the complexities of arranging the logistics for each session were becoming
increasingly apparent, so the protocol was changed to include a volunteer cofacilitator to aid both the
therapists and instructors for each group. Last, a minor amendment was made to the consent form,
including the additional clause ‘I agree that if I withdraw, or am withdrawn from the study for any reason,
then the researcher can continue to use the information I have already given them’ at the request of one
of the NHS research sites.
Amendment 2
The Social Network Scale (SNS)34 was added to the CRF in an attempt to record an objective measure of
the social network of participants.
Amendment 3
The Toronto Alexithymia Scale (TAS)35 and the Scale to Assess Negative Symptoms (SANS)36 Anhedonia
subscale item were replaced by the Clinical Assessment Interview for Negative Symptoms (CAINS)37 in the
CRF battery, a new instrument that follows a much closer conception of what we currently understand
negative symptoms to be.2
Amendment 4
The filming of the groups was extended to also include the physical activities arm of the study and the
CAINS interviews37 to enable inter-rater reliability assessments. A minor revision of the participant
information sheet and consent form was conducted in order to reflect these changes.
Amendment 5
During data collection, it was becoming apparent that a number of participants struggled to remember
historical information regarding the number and type of hospitalisations in addition to their medication
details. To rectify this issue, a final amendment to the protocol was made in order to allow research
assistants to check medical records to accurately source this data. A minor amendment to the consent
form was made, adding a clause through which participants could either consent or refuse permission to
access medical records. For participants who had already consented to take part in the trial prior to this
amendment being approved, an addendum to the original form was attached and additional consent was
sought in their next assessment.
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Eligibility criteria
Inclusion criteria
l Aged between 18 and 65 years.
l Diagnosis of schizophrenia according to the International Classification of Diseases, Tenth Edition
(ICD-10).
l Symptoms of schizophrenia present for at least 6 months.
l Scores of ≥ 18 on the negative symptoms subscale of the Positive and Negative Syndrome
Scale (PANSS).38
l No change in the type of antipsychotic medication prescribed within the previous 6 weeks (although
the dosage may change).
l A willingness to participate in a BPT or Pilates group.
l An ability to give written informed consent.
Exclusion criteria
l A severe physical disability or condition that prevents patients from participating in light activity.
l An insufficient command of English in relation to the nature of the group intervention and
assessment interviews.
Outcome measures
The primary outcome criterion used to test for the effectiveness of BPT was the change in negative
symptoms measured by the PANSS,38 completed at the end-of-treatment stage. The PANSS is a 30-item
semistructured interview that is designed to provide an overall measure of the symptoms of schizophrenia.
In the original format, 16 of the items relate to general psychopathology, seven items relate to positive
symptoms of schizophrenia (such as hallucinations and delusions) and seven items relate to negative
symptoms. Each item is rated on a scale of 1–7, covering both the severity and frequency of the symptoms
assessed, resulting in a range of 7–49 for positive and negative symptoms and 16–112 for general
symptoms. The subscales of the PANSS have been found to have good internal consistency,39 good
inter-rater reliability and concurrent validity,40 and the scale is recognised to be one of the established
symptom scales in schizophrenia research.41
As a exploratory outcome, the alternative Marder factor solution of the PANSS was also adopted, given
concerns that the original format includes some items that have more recently been found to relate to
cognitive, rather than negative, symptoms.42,43 In this alternative configuration, the ‘abstract thinking’ and
‘stereotypical thinking’ items are dropped, and replaced with the ‘active social withdrawal’ and ‘motor
retardation’ items. In addition to the Marder-configured subscale, the standard positive and general PANSS
subscale scores were also used as secondary outcomes to measure other aspects of psychopathology.
Other secondary outcomes include the Manchester Short Assessment of Quality of Life (MANSA),44
which measures aspects of both subjective and objective aspects of quality of life; the participants’
current objective social situation measured on the SIX;45 extrapyramidal symptoms measured on the
Simpson–Angus Scale (SAS);46 depression measured on the Calgary Depression Scale;33 an alternative
measure of negative symptoms that evaluates expressive and experiential deficits, CAINS;37 four items
taken from the Time Use Survey (TUS) to get a measure of the types of activities in which participants take
part; an adaptation of the Social Network Scale (SNS)34 to measure the frequency of their social contacts
over the past week; and, finally, participant satisfaction with the group into which they are randomised
using the Client Satisfaction Questionnaire (CSQ).47 In addition, the EQ-5D-5L (European Quality of Life-5
Dimensions, five-level version)48 and the Client Service Receipt Inventory (CSRI) were completed in order to
allow for an analysis of cost-effectiveness, cost–utility and cost impact of the intervention.49 All of the
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scales were completed at all three assessment stages (baseline, end of treatment and 6 months post
treatment) other than the CSQ, which was completed only at the end-of-treatment stage. For all scales,
interviewees were asked to report their symptoms and experiences over the previous week, apart from the
TUS, which collects information over the previous month; the CSQ, which aimed to assess the satisfaction
of the groups over the whole 10 weeks; and the visual analogue scale of the ED-5Q-5L, which asks
participants how they would rate the quality of their health on the day on the interview. At the baseline
assessment, the CSRI was used to assess the previous 3 months of service use, whereas at the
end-of-treatment and 6-month follow-up stages only the previous month was assessed. All outcome
measures were scored as part of a structured interview with the researcher.
The MANSA44 is a 16-item questionnaire that is designed to measure quality of life. The scale consists of
16 items: 12 covering subjective quality of life and four covering objective indicators. The 12 subjective
items are measured on a 1- to 7-point Likert scale, covering satisfaction with employment, finances,
recreational activities, friendships, safety, housing, health, sex life, family and overall life satisfaction. The
four objective items are ‘yes or no’ questions and cover whether or not the participant has been a victim
of a crime, has been accused of crime, has anyone he/she considers to be a close friend or has seen a
friend in the past 7 days. The summary score from the MANSA is calculated by taking a mean of the
12 subjective items, with a high score indicating a greater satisfaction with quality of life.
The SIX45 is an instrument designed to measure the individual’s objective social situation. The scale consists
of four questions: employment (whether or not he/she is employed, unemployed or taking part in
voluntary, protected work); housing (whether or not he/she has independent accommodation, sheltered/
supported housing or is homeless); the participant’s living situation (lives alone or with partner/family); and
friendship (has he/she met a friend in the past week). The responses of each item are added together,
resulting in a score ranging from 0 to 6, with a high score indicating a more positive social situation.
The CAINS37 is a recently devised assessment of negative symptoms, comprising 13 items, each rated on a
scale of 0–4. The first nine items relate to experiential/pleasure deficits, whereas the last four items relate
to expressive deficits of the disorder. For each subscale a mean score of the responses is calculated,
resulting in a range of 0–4 for both experiential and expressive deficits. In both cases a higher score
represents more severe psychopathology.
The Calgary Depression Scale33 is an assessment tool that is designed to measure depressive symptoms and
is specifically adapted for schizophrenic populations. In order to appropriately differentiate from negative
symptoms, which also include anhedonia and amotivation, the scale primarily focuses on the interviewee’s
low mood, hopelessness, feelings of guilt and perception of self. The scale comprises nine items, rating
from 0 (absent) to 3 (severe), giving a total range of 0–27, with a higher score representing a more
severe psychopathology.
The size of the participants’ social network was measured using a simplified version of the SNS, which was
first used in an observational study by Dunn et al.34 looking at the social life of long-stay patients. In this
study,34 the focus was on establishing the size of the social network in which participants typically
operated during their day-to-day lives. Participants were required to list all of the people to whom they
had spoken in the past week, identify their relationship to that individual and then report on how many
days in the past week they had spoken to them. Unlike in the original form of the schedule, participants
were not asked to report any additional details regarding the quality of their relationship with individuals.
The SAS46 is a scale designed to measure movement disorder symptoms that are related to extrapyramidal
side effects (EPSs). The scale includes 10 different items, rated from 0 to 4, with a higher score denoting a
greater severity of EPS. To rate each item, the assessors were required to observe different aspects of the
interviewee’s movement or physical appearance, such as his/her gait, severity of any tremor, and whether
or not he/she produces excess saliva, and, by conducting simple physical examinations, including checking
wrist, elbow and shoulder rigidity. Given that a significant proportion of assessments were conducted in
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the participant’s home, and by non-medically trained researchers, two items that required medical
apparatus, such as a medical table (head dropping and leg pendulousness), in addition to the glabellar tap,
were not conducted. Therefore, the adapted summary score produced for the purposes of this study
ranged from 0 to 32.
A measure of the number of activities in which participants took part was captured by the TUS. The aim of
the questionnaire was to provide a brief summary of the range of activities undertaken by the interviewee
over the previous week. The scale included four items: asking the participant whether or not they had
(1) eaten out at a café, restaurant, pub or wine bar; (2) been shopping for non-household/essential items;
(3) been to any type of place of entertainment, such as a club, bingo hall, cinema, museum or casino, etc.;
or (4) been on any outdoor trips, such as going to the park, beach or any other place of natural beauty.
Participants reported how many times they had been to each place in the past month, and for the length
of time for each time they went there. The items themselves were taken, and adapted, from an interview
schedule drafted by the Office for National Statistics to measure time use.50
The CSQ47 is a nine-item self-report questionnaire that assesses how satisfied the interviewee is with the
intervention they received. Each item is rated from 1 to 4, with a larger score representing a greater
satisfaction with the treatment.
The ED-5Q-5L48 is a scale that is designed to evaluate self-reported health-related quality of life, and was
used as the main outcome measure in the economic analysis. The scale consists of five items, which,
together, produce a summary score and a separate visual analogue scale. The item section of the
questionnaire asks the interviewee whether or not he/she experiences impairments in health (related to
mobility, self-care, conducting activities, pain/discomfort and anxiety/depression). These are rated as
‘1’ (no problems), ‘2’ (slight), ‘3’ (moderate problems), ‘4’ (severe problems) or ‘5’ (unable/extreme), and
this gives rise to 3125 distinct health states (from 11111 to 55555). These were weighted by standardised
value sets based on UK tariffs51 to estimate utility, which are anchored by ‘1’ (full health) and ‘0’ (death).
The weights attached to each health state are then combined using area-under-the-curve methods to
derive the total quality-adjusted life-years (QALYs) that are accrued over the follow-up period.
The visual analogue section of the EQ-5D-5L ranges from 0 to 100, and asks the interviewee to place a
cross on a continuous line, which would represent how they would rate their health today, with ‘0’ being
‘the worst health you can imagine’, and ‘100’ being ‘the best health you can imagine’.
The version of the CSRI49 used in this study aimed to assess the cost of services received and comprised
four discrete sections. The first related to whether or not the participant had been in contact with any
community health service providers and, if so, how many times and, on average, how long for. The second
part aimed to measure whether or not the participant had been in receipt of any specialised services,
related to physical or mental health, and the setting in which they were seen (i.e. inpatient stay, outpatient
hospital appointment or community services). The third section related to the type and amount of mental
health medication that he/she was prescribed. The fourth section measured the amount of sick days the
participant may have had, presuming that he/she was in employment. In any retrospective assessment
there is a trade-off between recall accuracy and obtaining a representative measure of service use.
Although one option would have been to assess service use over the whole intervening periods between
assessments, this was not conducted, as there were concerns that this would result in a loss of accuracy of
the data. Given that many of the participants would have had their condition for a prolonged period of
time, it was assumed that service use would be relatively stable. Consequently, only the previous month
was assessed at both the end-of-treatment and 6-month follow-up stages. For the purposes of this
investigation, informal care was not assessed, given concerns that there would be no way to obtain robust
measures in this context.
METHODS
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Service use measured with the CSRI was combined with relevant unit costs52,53 to derive total costs. These
costs include salary components, capital and administrative overheads and training, and are reported in
terms of face-to-face contact time with participants. The costs of the interventions were calculated using a
bottom-up microcosting approach, based on the time spent by professionals providing the intervention
(instructors), training (consultant psychiatrist) and supervision (therapist supervisor). The costs were divided
by the typical number of people attending a group (eight). The cost of one BPT or Pilates session was £9,
whereas training and supervision for the BPT instructors were estimated at £44.14 per participant receiving
the intervention.
In the original protocol, an assessment of non-verbal communication and gestural behaviours, using the
NEUROGES-ELAN system, was proposed.54 The NEUROGES-ELAN system is a coding and annotation tool
that is designed to analyse gestural behaviour. However, because of the difficulties in implementation,
gestural and non-verbal communicative behaviours were instead captured on an observational basis using
the CAINS expressive subscale.37
Blinding and randomisation
Randomisation was conducted by the Pragmatic Clinical Trials Unit (PCTU) based at Queen Mary University of
London [Clinical Trials Unit (CTU) Reg: 32], independent of the research team using a computer-generated
sequence. Participants were randomly allocated with equal probability to the intervention or control group,
stratified by region, in batches using randomly permuted blocks of four and six, beginning each batch at the
start of a new block to preserve balance. The Chief Investigator, all assessors and the trial statistician were
blinded to the treatment allocation until all end-of-treatment data were collected and the statistical analysis
plan was signed off. In order to prevent bias, eligibility and baseline assessments took place prior to
randomisation. Prior to each meeting with the research assistant, participants were reminded not to disclose
any details of the intervention in which they took part. In the event of unmasking, this was recorded,
specifying whether or not this occurred before or after the primary outcome measure (the PANSS assessment)
was completed.
Procedures
Participants were recruited from NHS mental health community services in five different Trusts: Mersey
Care NHS Trust, Greater Manchester West Mental Health NHS Foundation Trust, North East London NHS
Foundation Trust, South London and Maudsley NHS Foundation Trust, and East London NHS Foundation
Trust. The study was presented to clinical mental health teams, assertive outreach teams, recovery and
rehabilitation teams, early intervention services and clinicians who run the outpatient clinics in the area,
in order to provide information regarding the nature of the study. These clinicians were then asked to
identify all patients with a diagnosis of schizophrenia who had not recently changed their antipsychotic
medication and were presenting with negative symptoms, and to ask these patients for their consent to be
approached by a researcher. The clinicians who approached these potential participants were typically
psychiatrists, community psychiatric nurses or social workers, depending on the clinical setting from which
the participant was recruited. On the patient’s agreement, the researcher would then contact
him/her to arrange a meeting, during which he/she would be given an information sheet and an
explanation of the trial. Assessments were completed either in the patient’s home, local community
treatment sites or on university premises. After the patient had provided informed consent, a full PANSS
assessment was then conducted to establish whether or not he/she had a rating of at least 18 on the
negative symptoms subscale, as per the inclusion criterion, before being formally recruited onto the trial.
When participants gave their consent, eligibility relating to diagnosis and medication history was
confirmed, based on their medical records. Once approximately 16 participants at the study site were
recruited, researchers then recontacted patients in order to arrange a second meeting, during which the
full baseline assessment was conducted, including a second PANSS assessment. All assessments occurred
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within 1 month of the arranged group start date. The duration of the assessments ranged from
approximately 30 to 120 minutes, and the assessments were conducted either in the patient’s home, local
community mental health services or university premises.
After completion of the baseline assessments, the assigned trial ID numbers would be passed to a
statistician at the PCTU for randomisation. Once randomised, the relevant names, contact details and any
necessary risk information was then passed on to the Pilates instructor or BPT (depending on their
allocation) via the trial manager, who was the only research team member who was unblinded to
treatment allocations. The trial manager was not in direct contact with any participants, and was not
involved in any of the assessments that were completed. The cofacilitators then contacted the patients to
assist in the logistics of attending the groups, arranging taxi support if required. All of the groups took
place in local community hospitals, civic buildings, community arts spaces and disability support centres.
The design, implementation and the nature of the settings in which the groups took place remained
largely consistent throughout the duration of the study.
On completion of the BPT and Pilates groups, the researchers contacted the patients again in order to
complete an end of treatment assessment, which was required to be completed within 1 month of the
groups finishing. The end of treatment assessment involved all of the structured interviews and
questionnaires included in the baseline assessment CRF, in addition to the CSQ which was used to
measure the participants’ satisfaction with treatment. Six months after completion of the intervention,
the final follow-up assessment was conducted, which, again, included all of the same interviews and
questionnaires from the baseline assessment. Participants were paid £25 expenses for each assessment
interview that they attended.
Treatment and control conditions
Both BPT as the treatment condition and Pilates as the active control were delivered in 20 sessions of
90 minutes each, over a 10-week period, with two sessions each week, held on non-consecutive days.
Twenty sessions was deemed appropriate, given that this is the length that is specified in the manual, and
this has been found to be sufficient in two trials17,55 evaluating BPT as a treatment for severe mental illness,
and, in a review on music therapy, 16 sessions were sufficient to result in medium effect-sized improvements
in negative symptoms.56 Dependent on the randomisation, between 7 and 10 participants were assigned to
each BPT group or Pilates class, respectively. To limit the impact of any one body – psychotherapist or Pilates
instructor – on outcomes, each one was permitted to run a maximum of only two groups.
Treatment condition
The treatment under investigation was BPT, as outlined in an updated version of the manual used in the
2006 exploratory trial.17,57 The main goals of BPT as a treatment for negative symptoms in chronic
schizophrenia are to reconstruct a coherent ego structure through grounding and bodily awareness;
strengthen self-referential processes as a prerequisite for safe social interaction and reality testing; widen
and deepen the range of emotional responses to environmental stimuli; improve boundary demarcation,
enabling differentiation between self and other; and help patients to explore a range of expressive
and communicative behaviours, with the aim of reducing emotional withdrawal and improving
prosocial capabilities.
Each of the 20 sessions comprised five discrete sections. The first part was the opening circle, which aimed
establish the group as a therapeutic space, facilitate basic communication between participants, and
draw participants’ focus towards the body. Typical activities included breathing exercises, structured
communication activities and self-massage. The second section was the warm-up, which aimed to
promote self-awareness, emotional stimulation and reality-testing. In this section the focus is on physical
movements, exploring the personal kinesphere, general space and physical sensations. The third section
included structured tasks, aimed to address specific body image disturbances, such as boundary loss and
METHODS
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desomatisation. Techniques adopted included mirroring tasks, body sculpturing using ropes or art materials
and group tasks used to explore distinction between self and other. The fourth section centred on
creativity, including activities that support participants to use their bodies and movement as a source of
expression and pleasure. Tasks in this section included dancing, creating music or collage, or other
elements of play using various objects. In the final section, the closing circle, the time is used to disengage
from the therapy, and reflect on any events, thoughts or feelings that may have been brought up by
the session.
Each BPT group was facilitated by an Association of Dance Movement Psychotherapy (ADMP)-accredited
therapist, who had attended an additional two-day training course in delivering the intervention in its
manualised form. In each group the therapist was supported by a volunteer as cofacilitator. Each therapist
and cofacilitator received a minimum of three supervision sessions by a senior dance movement
psychotherapist over each group, either in person or via video link. In two cases, a fourth supervision
session was held in order to address specific issues that arose as the groups were ongoing. At the end of
every session, therapists completed a BPT session guide sheet (see Appendix 1) to assist in reviewing the
session and planning for the next. The principal aim of this exercise was to further encourage adherence to
the manual.
Adherence to the manual was assessed using a specifically developed adherence scale (see Appendix 2)
that was administered by body psychotherapists who were trained in assessing the sessions. A total of four
sessions, spanning one from each quartile, was selected from each group in order to ensure the continuity
of adherence over the whole 20-session treatment. Given that the first and final sessions adopted a slightly
different structure to the norm (the first session focused primarily on introducing the method to
participants, whereas the final session focused on planning for afterwards), they were omitted from the
adherence rating. In order to allow for the aspects of the intervention that relate specifically to group
process to be rated, only groups with a minimum of three participants in attendance were considered for
adherence rating. The scale assesses whether 10 core components of BPT have been implemented, with a
score of 0, 1 or 2 (no, limited, definite implementation) for each component. The total score ranges
therefore from 0 to 20.
Control condition
In order to mirror the structure of the BPT condition as closely as possible, the Pilates group was also a
90-minute, 20-session, twice-a-week intervention, which was held on non-consecutive days. The Pilates
group was described to patients as a fitness and physical health intervention, with the intention to limit the
risk of different acceptance rates of the two interventions once patients are informed about their
allocation. All of the classes were held in the same venues as the BPT groups.
Each class was facilitated by a Register of Exercise Professionals (REPS) level 3-qualified Pilates instructor
and assisted by a cofacilitator. Prior to the classes starting, a brief training session was arranged between
the instructor and an experienced clinician. During this meeting the instructors were provided with an
outline of the study, an explanation of what schizophrenia and negative symptoms are, what to typically
expect in the groups, and what to do if any untoward events or potential risk issues emerged. On any
occasions on which it was felt that the Pilates instructor may benefit from additional support, an additional
supervision session with an experienced clinician was arranged outside of the classes.
Prior to the groups starting, a brief Pilates guide was developed by the research team in collaboration with
instructors who were involved in the trial (see Appendix 3), using the Pilates Union Matwork Manual as a
guide.58 The intervention guide provided a brief summary of how to run the groups and a loosely
structured exercise plan, allowing for considerable flexibility to accommodate differing fitness levels
between participants. The use of props (other than mats and head blocks), music and additional activities
designed to encourage group interactions was not permitted. Instructors were advised to pay attention to
patients and respond to them without addressing or verbalising emotions and without promoting group
interactions, if possible.
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Sample size calculation
A 20% reduction in the PANSS score has been used as an indicator of clinically significant improvement in
the past,59 which, if applied specifically to the negative symptoms subscale, would equate to a difference
of between 3 and 4 points, given the eligibility criteria. To detect a difference of 3 points with a standard
deviation (SD) of 5, with 90% power for 5% significance, 58 patients were required in each arm. To allow
for clustering by group, an intraclass correlation coefficient (ICC) for treatment group of 0.1, and seven
patients per group with analysable data at the end of treatment, gives an inflation factor of 1.6, meaning
that 93 participants in each arm were required. At 6 months we predicted a loss to follow-up of 31%, so
recruiting 256 participants would leave 88 per arm at 6 months, and 91% power to detect a difference
of 3 points at this time point. One hundred and twenty-eight patients per arm, i.e. 16 groups of
approximately eight patients in each arm, would give 94% power for the end-of-treatment analysis,
assuming that 87.5% of patients have analysable data.
Analysis plan
Prior to conducting the analysis, an analysis plan was drafted by the trial statistician. The primary analysis
was of available cases of the PANSS negative subscale at the end of treatment, following intention-to-treat
principles. We used a mixed-effects model fitted by restricted maximum likelihood with fixed effects for the
treatment group, baseline PANSS negative scores (because it was expected to be highly correlated with
the outcome at end of treatment, so increasing the precision of the estimated treatment effect) and centre
(because it was used to stratify the randomisation), and random effects for therapy groups to allow for
clustering by group. Secondary outcomes were analysed using the same approach. To evaluate the impact
of missing data in a sensitivity analysis, multiple imputation of the data set was performed and the analysis
was replicated. The data were exported from Stata version 12 (StataCorp LP, College Station, TX, USA)
and missing data were multiply imputed in REALCOM-IMPUTE software60 to give 10 completed data sets,
using a multilevel model with therapy groups included as a random effect. These were imported back into
Stata, analysed and the results pooled using Rubin’s rules. Depending on whether or not the outcomes
were continuous, count or ordinal in nature, Stata’s xtmixed or xtmepoisson commands were used. In all
of the analysis, completed statistical significance was determined at p< 0.05.
In order to assess the impact of BPT in those who complied with treatment, a simple complier-average
causal effect (CACE) analysis was completed on all scales, which report a continuous outcome score
(the PANSS, CAINS, SAS, Calgary Depression Scale, MANSA and SIX). In contrast with the rest of the
analysis, a multilevel model was not adopted. Compliance was originally defined as attending at least
10 sessions; however, this was reduced to five sessions prior to the analysis plan being signed off following
a recent study55 evaluating the effectiveness of BPT for chronic depression, which found a significant effect
of treatment at this threshold.
In the final part of the analysis, preplanned subgroup analyses were conducted on the PANSS negative
subscale, the CAINS expressive and experiential subscales and the Calgary Depression Scale by fitting an
interaction term between the moderator of interest and the treatment group. The differences in treatment
response were explored between those with higher negative symptoms at baseline and a longer duration
of illness. High symptoms were defined as a score of > 23 on the PANSS negative subscale, whereas a low
score was ≤ 23. In an examination of the possible effect of duration of illness, two different cut-offs
were used. In the first analysis, participants with a duration of illness of > 5 years and ≤ 5 years were
compared, and, in the second analysis, those with a duration of illness of > 15 years and ≤ 15 years
were compared. All analysis was completed using Stata.
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Economic analysis plan
A health and social care perspective was adopted in the analyses, in line with NICE recommendations.
Costs were compared for the groups using a bootstrap regression model to account for non-normality in
the distribution of cost data. Missing costs and QALY data were imputed using a regression-based method
to estimate missing values based on other variables in the data set. The economic analysis was completed
by a health economist who was independent to the trial statistician.
Cost-effectiveness was assessed by estimating an incremental cost-effectiveness ratio (ICER) to show the
extra cost incurred by BPT to generate one extra QALY. This is defined as the cost difference divided by the
outcome difference, after adjusting for costs and outcomes measured at baseline. This is most meaningful
in the event of BPT being more (less) expensive and more (less) effective than Pilates; otherwise, one of the
alternatives is dominant (less expensive and better). However, there will inevitably be uncertainty around
the cost and outcome differences. To deal with uncertainty around the ICER, a cost-effectiveness plane
(CEP) and cost-effectiveness acceptability curves (CEACs) were created. For the CEP, 1000 bootstrapped
estimates of cost and outcome differences were produced, adjusted for baseline and plotted these against
each other. This then showed the probability that BPT had (1) higher costs and better outcomes; (2) higher
costs and worse outcomes; (3) lower costs and worse outcomes; or (4) lower costs and better outcomes
than Pilates. The CEAC was produced using the net benefit approach, for which the QALY difference is
multiplied by the societal value (threshold) placed on a QALY and the incremental service cost is subtracted.
A positive incremental net benefit means that BPT is more cost-effective and the proportion of positive
values for each societal QALY value gives the probability that BPT is cost-effective at that threshold.
In this study, the cost-effectiveness of receiving BPT rather than Pilates was examined. Both BPT and Pilates
are delivered by a therapist/instructor and in groups, so we estimated costs for both interventions.
However, in routine practice, BPT is likely to be considered as an additional service, rather than as an
alternative to other active therapies such as Pilates. Consequently, in a sensitivity analysis, the impact of
removing the Pilates group costs from the total costs in the control arm was explored.
Ethical considerations
The study received ethical approval from by the Camden and Islington National REC (REC reference
10/H0722/44) on 13 July 2010. The trial was overseen by an independent Data Monitoring and Ethics
Committee (DMEC), which reported to a TSC that was established prior to the trial start date. The TSC
consisted of researchers with experience of trial design and implementation in psychosis, a statistician and
a service user who had previously undergone a treatment of BPT.
During the study, all of the data were stored in line with the Data Protection Act and all video-recorded
data were encrypted and password protected on hard disk drives, which were locked in file cabinets. On
completion of the project, all of the data have been archived for a period of 25 years. In both study arms,
participants received input in addition to their treatment, and their standard care was not compromised at
any time. All patients were initially approached by a clinician who asked for their consent before they were
contacted by a researcher. Once contacted, all potential participants were fully informed about the study
and asked for written informed consent prior to enrolment.
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Patient and public involvement
Patient and public involvement came principally in the form of trial oversight. The TSC included a service
user who had previously attended a BPT group similar in nature to the therapy evaluated in the current
investigation. This service user provided input on which outcomes would be important to evaluate, and
reviewed the appropriateness of the measures used to evaluate these outcomes. In addition, they provided
input on the settings in which both of the assessments and groups should take place, emphasising the
importance of consistency throughout.
METHODS
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Chapter 3 Results
Participant recruitment and retention
The participant study dropout at each stage of the project is presented in the CONSORT (Consolidated
Standards of Reporting Trials) diagram (Figure 1). Recruitment took place from December 2011 until June
2013. In the study it was necessary to screen a far higher number of potential participants than anticipated
in order to recruit the required number. In total, 1371 individuals were identified as potentially eligible,
but, in the end, only 356 were recruited, of which 275 were randomised. This was due to a number of
factors. First, a relatively large number of screened patients were found to be ineligible, either because of
the potential participant subsequently being found to have a diagnosis of schizoaffective disorder or the
severity of negative symptoms being below the eligibility threshold. Second, given the group design of the
study once all of the therapy/control places were provisionally filled, no more participants were approached
unless a participant subsequently dropped out. Consequently, a number of participants were initially
screened as potentially eligible, but were not approached owing to the lack of available spaces on the trial
in their area. A relatively large number of potential participants declined to take part; however, given the
nature of the groups, the typical symptom presentation of the patients who would be eligible, and the
requirement to attend a group twice a week at specified times, this figure would not be
considered excessive.
Following randomisation, the study attrition rate was lower than anticipated. Of the 275 randomised, 266
(96.7%) were assessed at end of treatment and 255 (92.7%) went on to complete the 6-month follow-up.
In both cases this was significantly higher than the retention figures that were proposed in the protocol
and used for the sample size calculation. One participant died after completion of the groups as a result of
an illness that was not related to the intervention, and did not complete either the end-of-treatment or
6-month follow-up assessment. The data of this participant were omitted, leaving a final total of
274 participants who were potentially included in the analysis, presuming data availability.
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Patients identified as meeting
inclusion criteria by clinicians
(n = 1371)
Assessed and randomised 
(34 groups)
(n = 275)
Patients recruited 
(n = 356)
• Not contacted/unsuitable, n = 534
• Patients declined, n = 481
• No longer eligible, n = 33
• Withdrew, n = 48
Pilates
(17 groups)
(n = 135)
• Assessed, n = 127
• Not contactable, n = 2
BPT
(17 groups)
(n = 140)
• Assessed, n = 137
Patients excluded 
(n = 81)
Patients excluded 
(n = 1015)
• Withdrew, n = 2
• Patient deceased, n = 1
Patients lost 
(n = 3)
• Withdrew, n = 4
• Not contactable, n = 2
Patients lost 
(n = 6)
• Withdrew, n = 2
• Not contactable, n = 1
• Too unwell, n = 1
• Moved, n = 1
Patients lost 
(n = 5)
• Withdrew, n = 2
• Not contactable, n = 4
Patients lost 
(n = 6)
End of treatment 
(n = 137)
End of treatment 
(n = 129)
• Assessed, n = 131
6-month follow-up 
(n = 131)
• Assessed, n = 124
6-month follow-up 
(n = 124)
FIGURE 1 Consolidated Standards of Reporting Trials (CONSORT) diagram.
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Baseline characteristics
The baseline sociodemographic characteristics of the sample are presented in Table 1. Study participants
were, on average, 42.2 years old (SD= 10.7 years) and predominantly male (74%), unemployed (96%)
and living alone (57%). The baseline outcome scores for the whole sample are presented in Table 2. The
participants presented with moderate levels of negative symptoms (PANSS negative subscale score= 23.2,
SD= 4.3), mild positive symptoms (PANSS positive subscale score= 14.1, SD= 4.9) and low to moderate
symptoms of depression (Calgary Depression Scale score= 4.7, SD= 4.4). The level of inter-rater reliability
for the PANSS was high (PANSS total ICC= 0.85). Assessor blinding was maintained prior to the primary
outcome assessment in over 249 out of 264 of cases (94.3%).
TABLE 1 Descriptive statistics of participant characteristics at baseline, for experimental and control conditions
Variable BPT (N= 140) Pilates (N= 135) Total (N= 275)
Centre, n (%)
East Londona 41 (29) 40 (29) 81 (29)
North East Londona 8 (6) 8 (6) 16 (6)
South London 36 (26) 32 (24) 68 (2)
Manchester 23 (16) 23 (17) 46 (17)
Liverpool 32 (23) 32 (24) 64 (23)
Age (years) mean (SD) 41.1 (10.1) 43.3 (11.1) 42.2 (10.7)
Gender, n (%)
Male 103 (74) 100 (74) 203 (74)
Female 37 (26) 35 (26) 72 (26)
Ethnicity, n (%)
White 71 (52) 67 (53) 138 (52)
Black 39 (29) 38 (30) 77 (29)
Asian 13 (9) 16 (13) 29 (11)
Other 14 (10) 6 (5) 20 (8)
Employment, n (%)
Unemployed 131 (94) 132 (98) 263 (96)
Other 8 (6) 3 (2) 11 (4)
Living situation, n (%)
Alone 83 (60) 73 (54) 156 (57)
With others 56 (40) 62 (46) 118 (43)
Number of children, median (IQR) 0 (0–1) 0 (0–1) 0 (0–1)
Duration of illness (years), median (IQR) 11 (7–18) 10 (7–19) 11 (7–18)
Number of hospitalisations, median (IQR) 3 (1–5.5) 3 (2–5) 3 (1–5)
Medication: defined daily dose,b mean (SD) 1.48 (1.11) 1.71 (1.28) 1.59 (1.20)
IQR, interquartile range.
a These two centres were treated as one for the purposes of the stratified randomisation.
b Defined daily dose: 1.00= average maintenance daily dose for a drug used for its main indication. Only antipsychotic
medication considered.
DOI: 10.3310/hta20110 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 11
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Priebe et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
17
Uptake of interventions
The number of BPT and Pilates sessions attended are presented in Table 3. In the BPT arm, 106
participants (75.7%) attended at least 5 of the 20 sessions, thus fulfilling the minimum attendance
threshold required to be defined as a treatment complier in the CACE analysis. It was estimated that
approximately 25% of participants were provided with taxis to support attendance.
TABLE 2 Baseline outcome measures of the study sample
Outcome BPT group (N= 140) Pilates (N= 135) Total (N= 275)
n (%) Mean SD n (%) Mean SD n (%) Mean SD
PANSS
Negative 140 (100) 23.3 4.3 135 (100) 23.1 4.4 275 (100) 23.2 4.3
Positive 138 (99) 14 5.1 135 (100) 14.1 4.7 273 (99) 14.1 4.9
General 137 (98) 32.9 8.3 133 (99) 32.5 8.1 270 (98) 32.7 8.2
Total 135 (96) 70.1 13.6 133 (99) 69.5 13.3 268 (97) 69.8 13.4
PANSS Marder
negative
140 (100) 20.7 5.7 135 (100) 20.3 5.1 275 (100) 20.5 5.4
CAINS
Experience 136 (97) 22.1 5.6 134 (99) 21.5 5.5 270 (98) 21.8 5.6
Expression 140 (100) 8 3.5 133 (99) 7.5 3.9 273 (99) 7.8 3.7
Calgary Depression
Scale
140 (100) 4.8 4.2 134 (99) 4.6 4.6 274 (99) 4.7 4.4
MANSA 126 (90) 53.4 11.6 126 (93) 52.7 10.9 252 (92) 53 11.2
SAS 128 (94) 1.7 2.1 126 (93) 2.3 2.7 254 (92) 2 2.5
SIX 140 (100) 2.4 1.1 135 (100) 2.3 1.1 275 (100) 2.4 1.1
n (%) Median IQR n (%) Median IQR n (%) Median IQR
SNS
Friends seen 133 (95) 1 0.0–2.0 129 (96) 1 0.0–2.0 262 (95) 1 0.0–2.0
Family seen 133 (95) 2 1.0–3.0 129 (96) 2 1.0–4.0 262 (95) 2 1.0–3.0
Others seen 133 (95) 0 0.0–1.0 129 (96) 0 0.0–1.0 262 (95) 0 0.0–1.0
Total seen 133 (95) 4 2.0–5.0 129 (96) 4 2.0–5.0 262 (95) 3 2.0–5.0
TUS
Number of
activities
139 (99) 3 1.0–6.0 135 (100) 3 1.0–6.0 274 (99) 3 1.0–6.0
Time spent
(hours)
139 (99) 1.5 0.0–3.5 135 (100) 1.8 0.3–4.0 274 (99) 1.6 0.2–3.8
IQR, interquartile range.
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Therapist adherence to manual
Of the 17 different BPT groups, 16 were assessed for adherence to the manual using the BPT Adherence Scale
(see Appendix 2). One group was not assessed because of the lack of video data available for the sessions.
In total, 64 sessions (18.8% of all sessions conducted) were assessed. Overall, the therapist adherence to
the manual was relatively high, with a mean score of 17.6 out of the maximum of 20 (SD= 0.21). In all of the
groups there was evidence that the body psychotherapists were able to follow the structure of the sessions
as laid out in the manual, and establish a safe and cohesive therapeutic environment. Areas that were less
consistently implemented related to how the exercises completed related specifically to negative symptoms,
and the introduction of coping strategies that were designed to deal with negative symptoms specifically.
Primary outcome
The main outcomes of the trial are shown in Table 4. There was a small reduction in mean PANSS negative
symptoms between baseline and end of treatment in both the BPT and Pilates groups (within-group mean
reduction in the BPT group= 1.5, SD= 3.5; Pilates group= 1.5, SD= 3.8). After controlling for baseline
scores, study centre and therapy group, no significant difference between the treatment and control
condition was detected [adjusted difference in means= 0.03, 95% confidence interval (CI) –1.11 to 1.17;
p= 0.959, model-based ICC= 0.099].
Secondary outcomes
Significant reductions in mean SAS (–0.65, 95% CI –1.13 to –0.16; p= 0.009, ICC< 0.001) and mean
CAINS expression subscale (–0.62, 95% CI –1.23 to 0.00; p= 0.049, ICC= 0.022) were detected in the
BPT group compared with the Pilates group at the end of treatment. No other significant differences were
found in the secondary outcomes at this stage. In both groups, participants reported a high level of
satisfaction with the treatment they received (BPT CSQ= 25.3, SD= 4.6; Pilates CSQ= 25.9, SD= 4.0).
At the 6-month follow-up, no significant difference in means in the PANSS negative symptoms subscale
score was detected between the BPT and Pilates study arms (–0.18, 95% CI –1.68 to 1.32; p= 0.812,
ICC= 0.137). There was a significant difference in mean SAS scores at 6-month follow-up (–0.50, 95% CI
–0.97 to –0.07; p= 0.028, ICC ≤ 0.001). No other significant differences were detected on any other
outcome at follow-up.
TABLE 3 Number of sessions attended by those randomised to a group
Number of sessions attended BPT group (N= 140) Pilates group (N= 135) Total (N= 275)
0, n (%) 11 (8) 18 (13) 29 (11)
1–5, n (%) 30 (21) 40 (30) 70 (25)
6–14, n (%) 45 (32) 42 (31) 87 (32)
15–20, n (%) 54 (39) 35 (26) 89 (32)
Median number attended (IQR) 11 (5–17) 8 (1–15) 9 (2–17)
IQR, interquartile range.
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Ancillary analyses
Analysis following imputation
Multiple imputation of the data set was performed and the analysis was replicated in order to evaluate the
impact of missing data. During the study there was minimal participant dropout and, when the assessment
was conducted, the full assessment was completed in almost all of the cases. Consequently, only minimal
differences between the analysis of the imputed and non-imputed data sets were noted. The findings
are reported in Table 5.
TABLE 5 Adjusted differences in means between the groups at end of treatment and 6-month follow-up,
using the imputed data sets (intention-to-treat analysis)
Outcome (n= 274)
Adjusted difference in means/IRR at
end of treatment (95% CI)a
Adjusted difference in means/IRR at
6 months (95% CI)a
PANSSa
Negative 0.09 (–1.08 to 1.25), ICC 0.102 –0.09 (–1.58 to 1.39), ICC 0.135
Positive 0.07 (–0.70 to 0.84), ICC< 0.001 –0.19 (1.14 to 0.76), ICC< 0.001
General 0.26 (–1.38 to 1.89), ICC 0.087 –0.58 (–2.93 to 1.76), ICC 0.202
Marder negative 0.18 (–0.93 to 1.28), ICC 0.752 0.09 (–1.37 to 1.55), ICC 0.083
CAINS
Experience –0.3 (–1.34 to 1.28), ICC 0.069 –0.10 (–1.58 to 1.38), ICC 0.056
Expression –0.60 (–1.22 to 0.02), ICC 0.026 –0.30 (–1.06 to 0.50), ICC 0.031
Calgary Depression Scale 0.00 (–0.74 to 0.75), ICC> 0.001 –0.17 (–1.17 to 0.84), ICC 0.087
MANSA –0.17 (–0.37 to 0.02), ICC 0.033 0.07 (–0.20 to 0.34), ICC 0.074
SNS (IRR)b
Relatives seen 0.96 (0.81 to 1.14) 0.99 (0.77 to 1.27)
Friends seen 0.89 (0.62 to 1.27) 0.84 (0.60 to 1.18)
Total no. seen 0.97 (0.83 to 1.14) 1.00 (0.83 to 1.20)
TUS (IRR)b
Number of activities 1.11 (0.85 to 1.44) 1.05 (0.78 to 1.42)
Time spent (hours) 1.00 (0.74 to 1.36) 0.98 (0.72 to 1.34)
SAS –0.62 (–1.15 to –0.09) to ICC< 0.001c –0.58 (–1.07 to –O.09), ICC< 0.001c
SIX –0.03 (–0.17 to 0.12) to ICC< 0.001 –0.09 (–0.27 to 0.09), ICC 0.002
IQR, interquartile range; IRR, incidence rate ratio.
a Models adjusted for baseline measure of outcome, study centre and a random effect for therapy group (except CSQ).
ICC value denotes the model-based ICC where relevant.
b Median, IQR and IRR reported.
c Denotes significance at p< 0.05.
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In the PANSS negative subscale, no significant difference was detected between the experimental and
control condition either at the end of treatment (adjusted difference in means= 0.09, 95% CI –1.08 to
1.26; p= 0.885, ICC= 0.102) or the 6-month follow-up stage (adjusted difference in means= –0.09,
95% CI –1.58 to 1.39; p= 0.902, ICC= 0.135). In the secondary outcomes at end of treatment,
extrapyramidal symptoms were found to be significantly lower in the BPT arm (adjusted difference in
means –0.62, 95% CI –1.15 to –0.09; p= 0.021, ICC< 0.001). In contrast with the available case analysis,
the difference in the CAINS experience was not significant at the 5% level, despite only a minimal change
in the estimate (–0.60, 95% CI –1.22 to 0.02; p= 0.056, ICC= 0.026). At the 6-month follow-up, no
significant differences were detected between BPT and Pilates, other than in extrapyramidal symptoms
(–0.58, 95% CI –1.07 to –0.09; p= 0.021, ICC= 0.001).
Complier-average causal effect analysis
To estimate the causal effect of treatment accounting for departures from the randomised intervention, a
CACE analysis was conducted, using a minimum attendance of 5 and 10 BPT sessions to define those who
complied with treatment. The minimum attendance of five sessions was prespecified and the minimum of
10 sessions was exploratory in nature. The results are presented in Table 6, including both the estimates
for both 5 and 10 sessions as an indicator of compliance. In the primary outcome at end of treatment,
no significant adjusted difference in mean PANSS scores between BPT and Pilates was detected (–0.13,
95% CI –1.41 to 1.64). In the secondary outcomes, only a significant difference in means in the SAS was
detected (–0.82, 95% CI –1.51 to –0.12).
TABLE 6 Complier-average causal effect analysis estimates, using a minimum of 5 and 10 sessions of BPT
attendance as an indicator of compliance
Outcome ITT: coefficient (95% CI)
CACE: coefficient (95% CI)
Minimum 5 sessions Minimum 10 sessions
PANSS
Negative 0.09 (–1.08 to 1.25) 0.11 (–1.41 to 1.64) 0.15 (–1.89 to 2.19)
Positive 0.07 (–0.70 to 0.84) 0.09 (–0.93 to 1.11) 0.12 (–1.23 to 1.48)
General 0.26 (–1.38 to 1.89) 0.34 (–1.81 to 2.49) 0.45 (–2.41 to 3.31)
Marder negative 0.18 (–0.93 to 1.28) 0.23 (–1.22 to 1.69) 0.31 (–1.62 to 2.25)
CAINS
Experience –0.03 (–1.34 to 1.28) –0.04 (–1.76 to 1.68) –0.06 (–2.35 to 2.24)
Expression –0.60 (–1.22 to 0.02) –0.79 (–1.60 to 0.02) –1.05 (–2.15 to 0.03)
Calgary Depression Scale 0.00 (–0.74 to 0.75) 0.00 (–0.97 to 0.98) 0.01 (–1.30 to 1.31)
CSQ –0.83 (–2.05 to 0.40) –1.09 (–2.70 to 0.53) –1.45 (–3.60 to 0.70)
SAS –0.62 (–1.15 to –0.09)a –0.82 (–1.51 to –0.12)a –1.09 (–2.02 to –0.16)a
SIX –0.03 (–0.17 to 0.12) –0.03 (–0.23 to 0.16) –0.04 (–0.31 to 0.22)
MANSA –0.17 (–0.37 to 0.02) –0.23 (–0.49 to 0.03) –0.30 (–0.65 to 0.04)
a Denotes significance at p< 0.05.
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Subgroup analysis
Preplanned subgroup analyses were conducted in order to assess whether or not there was any difference
in response between participants with high and low symptoms, and between those with a long or short
duration of illness. The outcomes assessed included the PANSS negative subscale, the CAINS subscales, and
the Calgary Depression Scale. The composition of the subgroups for each instrument evaluated is reported
in Table 7, and the results of the subgroup analyses are presented in Tables 8–10. No significant differences
in response were detected in the primary outcome between patients with higher negative symptoms at
baseline (adjusted difference in means= 1.19, 95% CI –0.56 to 2.94; p for interaction= 0.184) or a longer
duration of illness, both when split at 5 years of illness duration (adjusted difference in means= –1.57,
95% CI –4.09 to 0.96; p= 0.224) and 15 years of illness duration (adjusted difference in means= –1.28,
95% CI –3.39 to 0.83; p= 0.234). With regards to the CAINS subscales and Calgary Depression Scale,
again no significant differences in response between the subgroups were detected.
TABLE 7 Numbers and proportions in each subgroup category for the PANSS, CAINS scale and Calgary
Depression Scale
Outcome Subgroup category N BPT, n (%) Pilates, n (%)
PANSS negative subscale PANSS negative < 23 129 63 (46.3) 66 (52.0)
PANSS negative ≥ 23 134 73 (53.7) 61 (48.0)
Illness ≤ 5 years 37 18 (15.8) 19 (18.1)
Illness > 5 years 186 96 (84.2) 86 (81.9)
Illness ≤ 15 years 155 79 (69.3) 76 (72.4)
Illness > 15 years 64 35 (30.7) 29 (27.6)
CAINS experience subscale PANSS negative < 23 129 63 (46.3) 66 (52.0)
PANSS negative ≥ 23 134 73 (53.7) 61 (48.0)
Illness ≤ 5 years 37 18 (15.8) 19 (18.1)
Illness > 5 years 186 96 (84.2) 86 (81.9)
Illness ≤ 15 years 155 79 (69.3) 76 (72.4)
Illness > 15 years 64 35 (30.7) 29 (27.6)
CAINS expressive subscale PANSS negative < 23 128 64 (48.1) 64 (51.2)
PANSS negative ≥ 23 130 69 (51.9) 61 (48.8)
Illness ≤ 5 years 36 18 (16.2) 18 (17.5)
Illness > 5 years 178 93 (83.8) 85 (82.5)
Illness ≤ 15 years 151 77 (69.4) 74 (71.8)
Illness > 15 years 63 34 (30.6) 29 (28.2)
Calgary Depression Scale PANSS negative < 23 129 63 (47.4) 66 (52.4)
PANSS negative ≥ 23 130 70 (52.6) 60 (47.6)
Illness ≤ 5 years 36 18 (16.2) 18 (17.3)
Illness > 5 years 179 93 (83.8) 86 (82.7)
Illness ≤ 15 years 151 76 (68.5) 75 (72.1)
Illness > 15 years 64 35 (31.5) 29 (27.9)
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TABLE 8 Difference in treatment response between those with high (≥ 23) and low (< 23) negative symptoms as
measured with the PANSS negative subscale
Outcome Adjusted difference in means 95% CI p-value
PANSS negative subscale (n = 263)
Treatment –0.57 –2.00 to 0.87 0.437
Illness severity –0.56 –2.23 to 1.11 0.510
Treatment × illness severity 1.19 –0.56 to 2.94 0.184
CAINS experiential subscale (n = 263)
Treatment 0.05 –1.54 to 1.63 0.955
Illness severity 0.42 –1.13 to 1.97 0.592
Treatment × illness severity –0.01 –2.16 to 2.15 0.997
CAINS expressive subscale (n = 258)
Treatment –0.16 –1.01 to 0.69 0.710
Illness severity 1.16 0.25 to 2.08 0.013
Treatment × illness severity –0.89 –2.03 to 0.26 0.130
Calgary Depression Scale (n = 259)
Treatment –0.59 –1.60 to 0.43 0.256
Illness severity –0.81 –1.84 to 0.22 0.123
Treatment × illness severity 1.19 –0.25 to 2.62 0.105
TABLE 9 Difference in treatment response between those with long (> 5 years) and short (≤ 5 years)
illness duration
Outcome Adjusted difference in means 95% CI p-value
PANSS negative subscale (n = 219)
Treatment 1.47 –2.00 to 0.87 0.437
Illness duration 0.79 –1.01 to 2.59 0.388
Treatment × illness duration –1.57 –4.09 to 0.96 0.224
CAINS experiential subscale (n = 219)
Treatment 1.01 –1.78 to 3.80 0.479
Illness duration 1.84 –0.29 to 3.97 0.090
Treatment × illness duration –0.68 –3.73 to 2.38 0.663
CAINS expressive subscale (n = 214)
Treatment 0.70 –0.82 to 2.22 0.367
Illness duration 1.57 0.40 to 2.76 0.009
Treatment × illness duration –1.60 –3.23 to 0.04 0.055
Calgary Depression Scale (n = 215)
Treatment –0.78 –2.66 to 1.10 0.413
Illness duration –0.08 –1.55 to 1.40 0.921
Treatment × illness duration 0.68 –1.38 to 2.74 0.517
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Adverse events
No serious adverse events occurred during the groups. During the follow-up phase, one participant died,
but this was unrelated to the trial or the intervention they received. Throughout the implementation of the
project there was no evidence of exacerbation of psychotic symptoms as a consequence of taking part in
the BPT or Pilates groups.
Economic analysis
Service use
The proportion of those who used different health services, and the mean number of contacts that these
participants made are presented in Table 11. At baseline, service use was broadly similar. Slightly more
participants in the Pilates group accessed their general practitioner (GP) services (70% in comparison with
61%) and, in those who did report making contact, a slightly higher number of appointments were made
in the Pilates group (mean= 2.1, SD= 1.5, in comparison with mean= 1.8, SD= 1.1). A higher proportion
of participants in the Pilates group reported regular contact with a social worker (39% in comparison with
24%) and general psychiatric outpatient contacts (51% in comparison with 43%), whereas in the BPT
group it was more common for participants to be in contact with a community psychiatric nurse (30% in
comparison with 20%). In the 3 months prior to the baseline assessment, only two patients, both in the
BPT group, reported a psychiatric inpatient admission. Almost all patients (97% of those in the Pilates
group and 99% in the BPT group) reported being on at least one mental health medication. Most were
prescribed antipsychotic medication, such as olanzapine (Zyprexa; Eli Lilly and Company), clozapine
(Clozaril, Novartis), flupentixol (Depixol, Lundbeck Ltd) or risperdal (Risperdal, Janssen Pharmaceutica) and
antidepressant drugs, such as fluoxetine (Prozac, Eli Lilly and Company), citalopram (Cipramil, Lundbeck),
mirtazapine (Remeron, Merck and Company) or sertraline (Zoloft, Pfizer).
TABLE 10 Difference in treatment response between those with long (> 15 years) and short (≤ 15 years)
illness duration
Outcome Adjusted difference in means 95% CI p-value
PANSS negative subscale (n = 219)
Treatment 0.56 –0.87 to 1.20 0.441
Illness duration –0.24 –1.81 to 1.34 0.770
Treatment × illness duration –1.28 –3.39 to 0.83 0.234
CAINS experiential subscale (n = 219)
Treatment 0.18 –1.20 to 1.66 0.795
Illness duration 0.09 –1.78 to 1.96 0.923
Treatment × illness duration 0.92 –1.63 to 3.47 0.479
CAINS expressive subscale (n = 214)
Treatment –1.61 –1.01 to 0.67 0.710
Illness duration 0.01 –1.00 to 1.02 0.983
Treatment × illness duration 0.03 –1.34 to 1.40 0.969
Calgary Depression Scale (n = 215)
Treatment –0.33 –1.26 to 0.61 0.495
Illness duration 0.13 –1.13 to 1.39 0.841
Treatment × illness duration 0.32 –1.39 to 2.04 0.711
RESULTS
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At both the end of treatment and the 6-month follow-up stages, again, only minimal differences between
the service use in the two conditions were apparent. A higher proportion of participants in the Pilates
group reported a contact with a social worker both at the end of treatment and at the 6-month follow-up
(29% in comparison with 22% at end of treatment, and 24% in comparison with 18% at 6-month
follow-up) and a greater number of GP contacts at 6 months’ follow-up (64% in comparison with 50%).
Participants in the BPT group reported more frequent contacts with a community psychiatric nurse at the
end-of-treatment stage [mean number of contacts= 2.2 (SD= 2.6) in comparison with 1.6 (SD= 1.1)] and
participants in the Pilates group reported more frequent contacts with other community services at the
6-month follow-up stage [mean= 8.6 (SD= 13.4) in comparison with 4.3 (SD= 4.9)]. All other figures
were broadly comparable across the two groups. In both conditions the number of psychiatric hospital
admissions reported at both assessment points was very low (1–2%).
The mean service costs for participants (not including the costs of the interventions) are presented
in Table 12. At baseline, the cost of service use was higher in the BPT group [£515 (SD= £1752) in
comparison with £417 (SD= £572)]; however, this was primarily attributable to the costs of two inpatient
admissions. Overall, the differences in costs at both end of treatment and at 6 months’ follow-up
were marginal.
The mean cost of the BPT intervention was £152 (SD= £63), while for Pilates it was £89 (SD= £60). Over
the whole follow-up period, the mean costs were £2297 (SD= £2835) for BPT and £2442 (SD= £3278) for
Pilates. Adjusting for baseline, BPT had mean costs that were £25 lower than for Pilates, but this was not
statistically significant (95% CI, –£671 to £721). In the sensitivity analyses when the costs of Pilates were
changed to zero, the BPT had costs that were on average £55 higher, which again was not statistically
significant (bootstrapped 95% CI= –£630 to £706).
TABLE 12 Cost of services use (excluding intervention) prior to baseline and follow-up assessments (2013/14, £)
Services
Baseline End-of-treatment follow-up 6-month follow-up
BPT
(n= 138)
Pilates
(n= 135)
BPT
(n= 134)
Pilates
(n= 127)
BPT
(n= 131)
Pilates
(n= 124)
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
General practitioner 68 105 79 95 40 60 50 88 51 87 63 77
Primary care nurse 8 26 9 28 1 5 2 7 1 7 2 10
Social worker 30 71 51 116 16 50 24 52 9 38 15 109
Community
psychiatric nurse
59 138 27 70 20 70 9 26 15 47 11 27
Care co-ordinator 3 7 4 15 17 45 25 64 8 17 10 21
Other community
service
33 130 49 198 17 81 17 80 15 85 21 104
Psychiatric inpatient 154 1642 0 0 103 858 85 718 221 1836 211 2351
Other inpatient 13 85 52 380 22 166 9 73 4 51 0 0
Psychiatric outpatient 77 149 78 101 48 120 59 112 38 77 47 91
Other outpatient 73 147 89 147 30 76 52 105 64 218 40 79
Total costs (£) 515 1752 417 572 314 912 334 800 428 1865 420 2367
RESULTS
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Assessment of quality-adjusted life-years
In the BPT group, the EQ-5D-5L values were 0.74 at baseline, 0.76 at end of treatment and 0.71 at the
6-month follow-up stage. The figures for Pilates were very similar: 0.76, 0.76 and 0.72, respectively.
The maximum QALY accrual was 0.69 (36 weeks divided by 52). The mean QALY accrual for the BPT
group was 0.517, whereas for the Pilates group it was 0.516. The difference adjusting for baseline was
0.008 in favour of BPT; however, this difference was not significant (95% CI –0.019 to 0.035).
Cost–utility analysis
The cost–utility results are presented in Table 13. The base-case results of the analysis suggest that BPT
has lower costs and produces more QALYs than Pilates; however, the differences in both cases were very
small and non-significant. Consequently, despite BPT being found to be technically dominant, any analysis
on which these estimates are based is likely to carry a substantial degree of uncertainty.
The CEP (Figure 2) indicates that there is a 37.9% chance that BPT is cheaper and produces more QALYs,
and a 35.4% chance that BPT is more expensive and produces more QALYs. Over 1000 replications, Pilates
was found to produce more QALYs in 26.7% of cases. As presented in the CEP (Figure 3), at £20,000 per
QALY there is approximately a 65% likelihood that BPT is more cost-effective than Pilates.
Cost-effectiveness of improving negative symptoms
In comparison with the Pilates group, participants in the BPT reported a slightly larger improvement by
the 6-month follow-up stage (difference in means= –1.6 in comparison with –1.4). Dividing the cost
by the difference in change scores (0.21) shows that BPT has lower costs and better outcomes, making
BPT the dominant option. However, difference between the groups was marginal. The ICER is £119, which
is the cost incurred by BPT to produce an extra unit improvement on this scale. As presented in the CEP
(Figure 4), there was a 33.5% chance that BPT was dominant (i.e. less costly and more effective) compared
with Pilates. The north-east quadrant, defining a scenario of BPT having higher costs and better outcomes,
has a 33.1% proportion of ICERs, whereas the south-west quadrant indicating lower costs and worse
outcome, is represented by the lower proportion of bootstrapped ICERs.
TABLE 13 Differences in incremental costs, effects and cost-effectiveness at 6 months’ follow-up
Cost of outcome category
BPT
(n= 140)
Pilates
(n= 135)
Incremental difference
(adjusted) 95% CI of difference
Health and social care costs,
£ (mean)
2297 2442 145 (25) –671 to 721
QALY (EQ-5D) 0.517 0.516 0.001 (0.008) –0.019 to 0.035
Incremental cost-effectiveness Dominant Dominated
PANSS negative score 21.8 21.5 0.3 (0.21)
Incremental cost-effectiveness Dominant Dominated
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FIGURE 2 Cost-effectiveness plane of 1000 bootstrap-replicated ICERs for BPT compared with Pilates, based on
health and social care costs and QALYs over 6 months, adjusted for baseline costs and utility.
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FIGURE 4 Cost-effectiveness plane of 1000 bootstrap-replicated ICERs for BPT compared with Pilates, based on
health and social care costs and negative symptom change over 6 months, adjusted for baseline costs and PANSS
negative subscale score.
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Chapter 4 Discussion
Study findings
In a study of 275 participants, no significant differences between BPT and Pilates were detected in the
PANSS negative symptoms subscale, either at the end of treatment or 6 months later. In the secondary
outcomes at the end of treatment, significant differences were detected in the CAINS expression subscale
and the extrapyramidal symptoms, both in favour of BPT. However, these differences are unlikely to be of
a sufficient size to represent a clinically meaningful benefit. At the 6-month follow-up stage, there was no
longer a significant difference in the CAINS expression subscale. However, a difference in extrapyramidal
symptoms was still present. These findings were consistent in the sensitivity analysis that was completed on
imputed data sets, and in the CACE analysis, in which those who attended at least 5 and 10 sessions of
BPT were defined as treatment compliers. No significant differences in outcome were detected between
those with high and low symptom scores, or with a long and short duration of illness. In the economic
analysis, no significant differences were found in service use or QALYS at the follow-up stage. In the
cost-effectiveness analysis, the results were marginally in favour of BPT. However, there was substantial
uncertainty in the estimates. Overall, there was no evidence that BPT is an effective treatment for patients
with negative symptoms of schizophrenia as compared with Pilates as an active control.
Interpretation
The study retention rates from randomisation to the 6-month follow-up were high. Over 90% of
participants remained in the study at 6 months’ follow-up, which was a far higher figure than anticipated.
The large sample size and minimal dropout meant that the study was highly powered (> 94%) to detect a
clinically important difference in the primary outcome. The inter-rater reliability for the PANSS was high
(PANSS ICC= 0.85), with no evidence of rater drift as the trial progressed. The BPT intervention was
manualised, and therapists were largely adherent to treatment, suggesting that the intervention had been
delivered as originally intended. Approximately 35% of participants who were approached declined to take
part in the study, which may appear quite high, but this was not unexpected, given that the physically
active nature of the groups and the fact many patients typically experienced prominent symptoms of
amotivation and asociality. With regard to those who did agree to take part, participants in the BPT group
attended a median of 11 sessions [interquartile range (IQR)= 5–17], whereas those randomised to the
Pilates group attended eight sessions (IQR= 1–15). Approximately 40% of participants randomised to the
BPT condition attended at least three-quarters of the sessions offered. This could be considered relatively
high and compares favourably with a similar trial in art therapy on this patient sample.8 In this study,8
participants typically reported a long duration of illness (median 11 years, IQR= 7–18), with multiple
hospital admissions (median 3, IQR= 1–5) and moderate negative symptoms (PANSS negative 23.2,
SD= 4.3). Overall, the participant characteristics of the sample should be considered to be both
representative of the schizophrenia population in secondary care in the UK and the types of patients who
would be considered appropriate for focused treatments for negative symptoms. Finally, given that the
intervention evaluated is not dependent on any particular health-care system, these findings should be
considered to be relevant to all countries that might consider using art therapies as a treatment for
negative symptoms of schizophrenia.
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One important limitation of the study is that, given the absence of any treatment-as-usual control group,
this study is unable to discount the possibility that BPT and Pilates may be equally effective in reducing
symptoms. If, indeed, this is the case then this reduction could either be attributable to the non-specific
effects of both groups, such as the provision of structured group activity and therapist attention, or
overlapping specific therapeutic factors, albeit delivered in different forms. In Pilates, the focusing on bodily
experiences on a cognitive and emotional level may not be explicit in a similar manner to that of BPT.
However, Pilates exercises that emphasise centring, concentration and a focus on breathing may foster
such links in a more subtle, implicit way. In support of this, the link between movement-based exercises,
such as Pilates and mindfulness, have been increasingly emphasised,29,30 which is important, given that
there is some evidence to suggest that mindfulness might help reduce negative symptoms.31 Furthermore,
although the facilitation of emotional group interactions in the Pilates groups was discouraged,
observations from the videotapes of the groups suggest that this did occur on occasions (particularly at the
beginning and end of groups), suggesting at least some degree of contamination may have occurred.
Although it is possible that both of the groups may have had an effect on negative symptoms, this appears
to be unlikely. The within-group reductions in both groups appear to be relatively small, with only a 1.5-point
reduction in the PANSS negative subscale in both the BPT and Pilates groups, which is half of the change
used to determine a clinically meaningful difference in the sample size calculation. In addition, although it is
impossible to determine what the change over time would have been in a control arm from the same
population investigated here, in a recent meta-analysis looking at the change in negative symptoms over
time in schizophrenia outpatients this reduction appears comparable with placebo/treatment-as-usual
conditions,61 suggesting that the groups provided little additional benefit. Given that the symptom change in
the Pilates group was similar to control conditions from other studies, it suggests that adopting Pilates as a
comparator was appropriate, with the findings generalisable to other active controls, presuming that they do
not provide any additional clinical benefit over treatment as usual either.
Another possible limitation is that, being only 20 sessions long, the treatment under investigation was
relatively short, given the population recruited. The participants were typically stable, highly chronic in
nature and had experienced multiple hospital admissions over the course of their illness, so it may be
somewhat ambitious to expect substantial, lasting changes over only a 10-week treatment. In support of
this, a meta-analysis looking at a different form of arts therapy – namely music therapy – suggested that
> 40 sessions were required before large effect sizes could be detected in the treatment of negative
symptoms.32 However, the same meta-analysis also found that a small effect could be expected in as few
as three sessions, whereas in this study the CACE analysis did not detect a significant improvement in
those who attended at least five sessions and 10 sessions, respectively. Therefore, although it remains
unclear whether or not more prolonged exposure to the therapy would result in clinically significant
changes to negative symptoms, the lack of any effect at all in participants who did comply with treatment
suggests that this may be unlikely.
In this study, participants who were randomised to the BPT group attended significantly more sessions
than those who were randomised to the Pilates group. The reasons for this are not entirely clear. One
possible reason could be that, as experienced clinicians, the body psychotherapists were likely to have a lot
more experience at engaging people with severe mental health problems. A second possibility might be
that given the BPT treatment administered was designed specifically for this clinical population, it may have
been easier for the participants to engage in and more appropriate to their capabilities. In support of this,
despite the Pilates group being run at a beginner’s level, some participants did report having difficulty in
conducting the exercises, and particularly when attendance was sporadic. A third possibility might be
related to participant treatment expectation, with people more motivated to take part in a ‘therapy’ as
opposed to a ‘control’ arm. Finally, higher attendance may have related to patient preference, with
patients actually preferring BPT, even if it did not appear to result in significantly improved outcomes
over the Pilates.
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Generalisability
The findings from this study are in contrast with those in the explanatory trial that was included in the
NICE review of arts therapies.6,17 In that small-scale exploratory study,6 a significant reduction in negative
symptoms was found in the BPT group in comparison with a supportive counselling control group. One
possible reason for the difference could be that In the exploratory trial the minimum level of negative
symptoms as an inclusion criteria was set higher (at least 21 on the PANSS negative subscale in
comparison with at least 18 in the present study). However, no significant difference in treatment response
was detected in the subgroup analysis that compared participants with PANSS negative scores above and
below a score of 23 at baseline. Another possible explanation for the difference between the findings is
that in the exploratory trial there was no active control, so effects could be attributable to the non-specific
effects of structured group activity. However, the within-group changes in this study do not support this
given they were more comparable with that found in the supportive counselling group of the exploratory
trial (difference in means= –1.3) as opposed to the BPT group (difference in means= –4.5). One other
possible explanation is the less rigorous blinding in the exploratory trial. It was estimated they could have
been unblinded on as many as 50% of occasions at the end-of-treatment stage, and there were
insufficient personnel for a different assessor at the follow-up stage when unblinding did occur. In the
present study, blinding was maintained up until the primary outcome in 94% of cases, and in the event of
an assessor becoming unblinded, efforts were made for a different researcher to conduct the follow-up
assessment. Consequently, it is quite possible that the assessor expectations of improvement in the
exploratory trial may have led to bias in the rating values.
The findings of this study also appear to contrast with earlier investigations into body-orientated
treatments for negative symptoms.20–22 However, all of these investigations appear to have serious
methodological shortcomings. In the Darby study,21 for example, only 15 participants were recruited in
each intervention arm; the interventions themselves consisted of only one session, lasting approximately
15 minutes in total; the participants’ perceptions of the body were using a Holtzman Inkblot Test,62
as opposed to any standardised measure of negative symptoms, and differences in pre–post scores
immediately before and after the intervention were evaluated, rather than comparing the effectiveness
directly with a control condition. In the Nitsun et al. study,22 only 12 participants were recruited into the
control and experimental arms; analysis was conducted within groups, rather than between groups;
functioning and body image were assessed using non-standardised methods, such as the Rorschach test63
and an unpublished draw-a-person body image scale; and it is unclear whether or not the improvements
detected were a consequence of the non-specific effects of increased therapist attention (particularly given
the large number of therapists and cofacilitators that both the treatment and control interventions
adopted). In the Goertzel et al. study,20 although the sample size was larger than the other trials, there
were significant issues with regards to symptoms assessment and statistical analysis. Improvements were
measured by unstandardised reports of psychiatrists (who were blinded) and nurses (who were not
blinded) at the end of treatment only. Given that the baseline measures were not conducted, it is unclear
whether or not any differences between the groups may be attributable to patients being different at
study entry (particularly given that the details of the randomisation procedure are not provided).
In addition, although significant differences were detected in four different areas (overall improvement,
affective contact, mobility and general functioning), in 17 other measures no significant differences were
detected and no primary outcome was prespecified, which leads to the possibility that any differences
detected may be attributable to chance findings from multiple testing. Lastly, in a study by Andres et al.,64
only 10 participants were recruited, there was no comparator, and only physiological measurements and
participants’ self-perceptions were assessed. These would not necessarily be indicative of negative
symptoms, and are likely to be influenced by regression to the mean. Overall, although there are some
historical findings that contradict the findings of this study and support the use of body psychotherapeutic
techniques in the treatment of schizophrenia, considerable caution would be recommended in interpreting
these study findings.
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The findings of this study mirror those reported in the MATISSE trial,8 which evaluated conventional art
therapy, rather than BPT. However, in the NICE guideline arts therapies review,6 no such distinction is
made between modalities. The positive results in studies in that review, which included small-scale studies
both on BPT12 and art therapy,37,38 have not been replicated in either the present trial or in the MATISSE
study,8 which were both much larger. Therefore, although the findings of this study and the MATISSE
study8 do not necessarily preclude the possibility that different types of arts therapies (such as music
therapy) may still be effective, they are not consistent with the current NICE recommendation that all types
of arts therapies should be considered as a treatment for negative symptoms or schizophrenia, and,
furthermore, do not support the evidence on which the NICE recommendation was initially based.
The MATISSE trial8 followed a highly pragmatic design, aiming to evaluate art therapy as it is delivered in
routine practice in the UK. Although providing a close approximation of what could be delivered in ‘the
real world’, the study7 was criticised for a lack of clarity of the model of treatment being evaluated8,9
(although this critique has since been disputed).11 In the trial that we conducted, the mechanism of action
and model of implementation were clearly defined in a treatment manual designed prior to the study
taking place, and adherence to the method was assessed to ensure that the treatment was appropriately
delivered. Although this offers a significant advantage over the more pragmatic design that was delivered
in the MATISSE study,8 this does also have a number of limitations. First, it can be disputed that the
intervention that we assessed may deviate from current routine practice, weakening the generalisability of
the results, and, second, given that the intervention delivered by the therapists may deviate from typical
practice, this may result in a performance bias. With regard to the second point, there is some evidence to
suggest the effectiveness of a complex intervention increases as the therapists become more experienced
in implementing the therapy in a research context, given that it may differ from their usual practice and
require different competencies.65 In this study, the body psychotherapists were typically highly experienced
in working with this clinical population; however, conducting a maximum of only two groups may have
meant that there was insufficient time for therapists to gain experience of working within the confines of a
clinical trial. Given the different strengths and weaknesses of the methodologies used by both this study
and the MATISSE trial,8 the consistency of the findings between the two trials add considerable weight to
the conclusion that arts therapies, as they are currently defined, should not be considered an effective
treatment for negative symptoms of schizophrenia.
In the secondary outcomes, a small significant improvement in the BPT group was detected in expressive
symptoms, as measured by the CAINS at end of treatment, and in movement disorder symptoms both at
the end of treatment and at 6 months’ follow-up. For both findings it is important to consider that
multiple testing was conducted, and therefore these observed differences may be attributable to an
inflated type 1 error. To date, no studies have evaluated to what extent improvements in the CAINS
subscales equate into clinically meaningful benefits, unlike with the PANSS.39 However, the only marginal
difference detected between the groups in the CAINS experiential subscale suggests that the
improvements are unlikely to translate into a clinically meaningful change. In any case, the significant
difference was not maintained 6 months later. Regarding the change in movement disorder symptoms
detected, given that a number of items from the SAS scale could not be scored during the assessments,
one should, again, be somewhat cautious in how these findings are interpreted. Although it is intuitive to
consider that a treatment focusing specifically on the body may help alleviate movement-related
symptoms, it would be advisable to re-examine this finding, using a fully validated scale to measure such
symptoms, before any firm conclusions can be drawn.
Overall, this study does not support group BPT as a treatment for negative symptoms of schizophrenia.
In conjunction with the MATISSE trial,8 these findings are not consistent with the NICE recommendations6
for arts therapies as a treatment for negative symptoms of schizophrenia. However, patients with severe
negative symptoms showed relatively good attendance in both group conditions and follow-up rates were
very high. This suggests that it is possible to implement rigorous trials with this challenging patient group,
and that the format might be appealing. Future research could build on this promising experience, even if
the specific methods of interventions will have to be different.
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Chapter 5 Conclusions
Implications for health care
In comparison with an active control, group BPT does not have a clinically relevant beneficial effect in the
treatment of patients with negative symptoms of schizophrenia. BPT was not found to result in clinically
meaningful benefits over and above an active control, and no significant difference was detected in either
outcomes or costs in the cost-effectiveness analysis.
These findings are not consistent with the current NICE guidelines,6 which suggest that art therapies may
be an effective treatment for negative symptoms. In conjunction with the recent findings of the MATISSE
trial,8 our findings suggest that these recommendations may require amending. At this stage we are
unable to determine whether arts therapies, as a whole, are not effective for this patient group or it is just
that BPT and art therapy, specifically, are not effective. This being the case, it is still not clear whether
the recommendation of arts therapies for this patient group should be withdrawn or amended so that the
individual types of arts therapies are separately evaluated.
Whereas no improvements in the primary outcome was detected in those who were randomised to
the BPT group, significant improvements in movement disorder-related symptoms were detected, and
these improvements were maintained 6 months later. Although caution should be advised in interpreting
this result, given the fact that the SAS used was not fully administered, improvements in this area were not
anticipated beforehand and patients were not recruited with this particular issue in mind, it does suggest
that body-orientated therapies may be a possible avenue to treat movement-related symptoms.
Despite the BPT and Pilates groups not appearing to provide any clinically meaning benefit, the relatively
high attendance in both arms was notable, given that this patient group reported moderate levels of
anhedonia, avolition and asociality. In addition, in both groups, participants reported a high level
of treatment satisfaction when assessed at the end of treatment. These results suggest that even if these
active interventions do not have a direct impact on negative symptoms, organised, regular group activity
can be attractive to this patient group. Offering such groups may be a way to decrease social isolation
and increase physical activity levels, which is important, given the associated physical health benefits.36
In addition, the high participant attendance shows that trials evaluating such interventions can be
successfully implemented in the community.
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Recommendations for research
1. An update of the NICE review6 examining the effectiveness of arts therapies as a treatment of negative
symptoms of schizophrenia may be required, following the results of both this study and the MATISSE
study.8 These two studies include significantly more participants than all of the studies currently
included in the review combined (n= 692 compared with n= 382). Including a network meta-analysis
comparing the effectiveness of different art therapy types may be especially informative.
2. Evaluate the effectiveness of BPT as a treatment for negative symptoms over a greater number of
sessions. Other psychosocial treatments for schizophrenia, such as cognitive rehabilitation therapy, are
typically administered over 40 sessions,66 so it is feasible that more sessions may be required for BPT to
be effective.
3. Conduct a full-scale RCT examining the effectiveness of music therapy as a treatment for negative
symptoms of schizophrenia to help determine whether or not treatment outcomes are different
between different art therapy types.
4. Evaluate the possibility of BPT as a treatment of EPSs resulting from medication side effects, following
the significant improvements detected in the SAS.
Other information
Protocol
The protocol for the study was published in the open access journal BMC Psychiatry (www.biomedcentral.
com/1471–244X/13/26).
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Appendix 1 Body psychotherapy session sheet
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Appendix 2 Body Psychotherapy Adherence Scale
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Appendix 3 Pilates guide
Information for all Pilates instructors on the ‘NESS’ trial
The programme overleaf has been devised by Pilates instructors already involved in the Research Trial.
Although it might sound quite rigid, we are happy for there to be a degree of flexibility at the discretion of
each instructor, so adding an increase in the number of exercises earlier if group is advancing quickly, or
increasing the warm up if clients are struggling to get a handle on correct breathing at the beginning, etc.
is entirely appropriate. The intention behind devising this is not to sound too prescriptive, but to ensure
that what is being delivered is consistent between instructors, and universally recognisable as a
Pilates class.
With this being a research trial, the most important consideration for us is that what is being delivered is
a ‘pure’ Pilates class, meaning additional psychotherapeutic or mindfulness/yoga techniques are not
incorporated into the sessions. The reason behind this is because if any improvement in outcomes in the
Pilates is detected, it will be impossible to identify whether this is attributable to the Pilates groups
themselves or the additional therapeutic input provided. We would encourage all instructors and
cofacilitators to be warm and polite to all participants; however any additional support, guidance or
counselling to the participants should be avoided. All participants are receiving ongoing care in NHS
services, so the participants will be in continual contact with trained professionals to provide any additional
help they should need.
What is the purpose of the trial?
The purpose of the study is to examine the effectiveness of a manualised form of group body psychotherapy,
specifically designed to reduce the negative symptoms of schizophrenia. The treatment has been found
to be effective in comparison with supportive counselling in an earlier, small-scale study; however, it is
currently unclear whether this is down to the psychotherapeutic component of the treatment or the
structured physical activity delivered in a group setting. By comparing the effects of the treatment to a
similarly structured Pilates group, we can examine whether the psychotherapeutic component is causing
any additional reduction in negative symptoms over and above what we might expect from structured
group activity.
What is schizophrenia, and what are negative symptoms?
Schizophrenia is a chronic, disabling condition effecting approximately 1% of the population. The
symptoms of schizophrenia fall into three broad categories: positive symptoms, which can include
hallucinations, unusual or bizarre beliefs, and unusual ways of thinking; cognitive symptoms, which can
include an inability to understand or make use of information, attention deficits and memory problems;
and negative symptoms, which can include flat affect, an inability to experience pleasure, reduced
motivation and social withdrawal. Antipsychotic medication has been found to be effective in treating
positive symptoms; however, the negative and cognitive symptoms are much more resistant to medication,
hence the need to explore alternative therapies.
What is a Randomised Controlled Trial (RCT)?
A RCT is a type of experiment most commonly used to test the safety or effectiveness of an intervention in
health care. Once a participant has been successfully recruited, but before the treatment begins, they are
randomised into one of the treatment arms, and at the end the outcomes are compared. In this study,
once 16 participants are recruited, 8 will be randomly assigned into the body psychotherapy group, and
8 in the Pilates class. Assessments will occur before treatment, after treatment and at 6 months’ follow-up,
with the outcomes then compared to each other.
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Who is ‘blinded’, and what is it?
The Research Assistants (RAs), who recruit the participants and conduct the assessments will be blinded to
the intervention allocation, which means they will not know whether the participant attends the Pilates
or body psychotherapy group. The reason this is done is to try and minimise any effect of the RAs
expectations on how effective an intervention is, which can unduly influence the assessment of how
effective an intervention is. In drug trials it is usually the case for participants to also be blind to their
allocation for the same reason; however, given they will be taking an active part in the trial this will
obviously not be possible in this situation. The Trial Manager will not be blind to the allocation, as he will
not be doing any assessments, so if you need to talk to the research team about a participant you should
contact him.
What risks can we anticipate in the study?
We anticipate minimal risks to both instructors and participants in this study. All patients will be
outpatients receiving ongoing care in NHS services, and deemed sufficiently stable to take part by their key
worker and the research team after a risk assessment. As with any physical activity, there is a small chance
of contracting injuries; however, there is a wide consensus that the benefits of physical activity overall
outweigh such risks. Any participants not able undertake light physical activities will be ineligible to take
part in the study.
What do I do if any adverse events/serious adverse events (AEs/SAEs) occur?
If any adverse events either occur or are identified during the course of the group, it is the responsibility of
the instructor to notify the Trial Manager by telephone (see number below). In the case of any serious
adverse events (SAEs) please do not hesitate to contact the emergency services as appropriate.
Who are the cofacilitators and what is their role?
The cofacilitators are volunteers who have agreed to assist both in delivering the class, and in performing
some of the more practical elements involved in running the groups, such as setting up the video cameras
and contacting non-attendees. The volunteers will not be qualified Pilates instructors, and so will not
take any part in leading the group. In the majority of cases the volunteers will either be psychology
graduates/undergraduates, and/or have some experience of working with mental health populations.
As with the instructors, it is important that no volunteers provide additional psychotherapeutic input.
If you need to discuss the Trial with any member of the research team please contact the Trial Manager
on [XXXX].
The NEgative Symptoms of Schizophrenia (NESS) 20-session
Pilates programme:
l The group is to be delivered twice a week over a period of 20 weeks, with each session lasting
90 minutes.
l The agreement was to initially start with 25- to 30-minute warm-up sessions, followed by ≈6 exercises
from the list, appropriate to level.
l As the class progresses, gradually reduce the duration of the warm-up period to nearer 15–20 minutes
by the 20th session in order to include more exercises. The exercises listed below are not in any set
order, and have only been included as a guide. Some may be too advanced for this client group, whilst
there may be other exercises not listed which are more appropriate.
l At approximately eight sessions, begin to add ≈2 exercises every four sessions, up to a total of around
12 exercises by session 16.
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Warm-up
Breathing.
Imprinting.
Hip release.
Supine spinal rotation.
Cat stretch.
Hip rolls.
Scapula isolation.
Arms circle.
Head nods.
Elevation and depression of scapulae.
Exercise list
Ab prep.
Breast stroke preps 123.
Shell stretch.
Hundred.
Half roll back.
Roll up.
One leg circle.
Spine twist.
Rolling like a ball.
Single leg stretch.
Obliques.
Scissors.
Shoulders bridge prep.
Breast stroke.
Shell stretch.
Neck pull prep.
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Obliques roll back
Side kick side leg-lift series 12345.
Spine stretch forward.
Single leg extension.
Swan dive prep.
Swimming prep.
Leg pull front prep.
Seal.
Side bend prep.
Push up prep.
Double leg stretches.
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Appendix 4 Client report file
PANSS – Re-ordered (includes sample prompts) 
a) Patient ID     c) Baseline/ EOT/Follow-up (circle)    
            
b) Assessors signature:  d) Date                      
 
 
G1 Somatic concern (physical complaints/beliefs about bodily illness or malfunctions) 
 
How has your physical health been in the last week? 
Do you ever worry that you have something wrong with your body?  
Do you have a physical illness or disease?  
Does your head or body ever feel strange?  
Or do you have a problem with the way your body has been functioning? 
Has your head or body changed in shape or size? 
If answer is YES to any of the above:  
How serious is the problem? 
What is causing the problem? 
 
1 The definition doesn’t apply 
2 Questionable pathology – patient may be upper extreme of normal limits 
3 Distinctly concerned about health or somatic issues, evidenced by occasional questions or desire for reassurance 
4 Complains about poor health/body malfunction, but no delusional conviction, and over-concern can be allayed by 
reassurance.  
5 Patient expresses numerous or frequent complaints about physical illness or bodily malfunction, or reveals 1 or 2 
clear cut delusions involving these themes, but is not preoccupied by them.  
6 Patient is preoccupied by one or a few clear-cut delusions about physical or organic malfunction, but affect is not 
fully immersed in these themes, and thoughts can be diverted by the interviewer with some effort. 
7 Numerous and frequently reporting somatic delusions, or a few with catastrophic nature. Which dominate affect and 
thinking. 
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G2 Anxiety (experiences of nervousness, worry, apprehension, or restlessness) 
 
Do you find that you worry about things a lot? 
Have you been feeling nervous/tense/afraid within the last week? 
If YES,  
How anxious have you been feeling on a scale of 1 to 10, with 10 being the most anxious you could ever 
feel? 
 
If answer is YES to any of the above: 
Are you afraid of something/or someone? 
Do you ever get into a state of panic? Or feel shaky/faint/sweaty as a result of feeling anxious? 
Definition of panic attack = a feeling of intense fear and anxiety which usually comes on quite suddenly and 
lasts for a brief amount of time. During an attack, people usually have unpleasant bodily sensations such as: 
rapid heart beat, breathing very fast, feeling short of breath, chest pains, feeling faint or dizzy, trembling and 
sweating.  
 Have your worries or nervousness affected your appetite/sleep/ability to work in the last week? 
 
1 The definition doesn’t apply 
2 Questionable pathology – patient may be upper extreme of normal limits 
3 Some worry, over-concern or subjective restlessness, but no somatic/behavioural consequences are reported or 
evident 
4 Patient reports distinct symptoms of nervousness, reflected in mild physical manifestations (e.g. fine hand 
tremors/perspiration) 
5 Serious anxiety problems which have significant physical/behavioural consequences (e.g. marked tension, poor 
concentration, palpitations, impaired sleep) 
6 Almost constant fear associated with phobias, marked restlessness or numerous somatic manifestations 
7 Life seriously disrupted by anxiety which is present almost constantly, and at times reaches panic proportion or is 
manifested in actual panic attacks. 
 
 
G3 Guilt feelings (self-blame for real or imagined misdeeds in the past) 
 
Do you tend to blame yourself for things that have happened? 
Do you feel guilty about something you may have done in the past? 
Do you ever feel like you deserve punishment for something you have done?  
 
If YES,  
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What kind of punishment do you deserve? 
What do you deserve punishment for? Is there a particular incident you have in mind? 
Have you had thoughts of harming yourself as one kind of punishment? Have you ever acted on those 
thoughts? 
 
1 The definition doesn’t apply 
2 Questionable – patient may be upper extreme of normal limits 
3 Questioning elicits a vague sense of guilt/self blame for a minor incident, but is clearly not overly concerned 
4 Expresses distinct concern over responsibility for a real incident but is not preoccupied by it, and attitude/behaviour 
are essentially unaffected. 
5 Patient expresses strong sense of guilt associated with self-deprecation or the belied that he/she deserves 
punishment. The guilt feelings may have a delusional basis and may be volunteered spontaneously, may be a 
source of pre-occupation and or depressed mood, and cannot be allayed readily by the interviewer. 
6 Strong ideas of guilt that take on delusional quality – lead to hopelessness and worthlessness. Patient believes 
he/she deserves harsh sanctions for the misdeeds, and may regard his/her current life situation as such 
punishment. 
7 Patients life dominated by unstable delusions of guilt, for which he/she feels deserving of drastic punishment (e.g. 
imprisonment, torture, death). There may be associated suicidal thoughts or attribution of others’ problems to one’s 
own past misdeeds. 
 
 
G6 Depression (feelings of sadness, discouragement, helplessness and pessimism) 
What has your typical mood been like in the last week? 
Are you mostly happy or sad? 
Have you had periods of feeling sad and hopeless in the last week? 
 
If patient is mostly sad: 
How unhappy have you been feeling on a scale of 1 to 10, with 10 being the most 
unhappy you could feel? 
When do you feel the saddest? How long do these feelings last? 
Do you sometimes cry? How often? 
Has your low mood affected your appetite/sleep/ability to work? 
Do you have less or nearly no interest that you used to in your leisure/social activities 
or hobbies or things you used to enjoy? 
Have you had thoughts of harming yourself? 
 
1 The definition doesn’t apply 
2 Questionable pathology – patient may be upper extreme of normal limits 
3 Expresses some sadness or discouragement only on questioning, but there is no evidence of depression in general 
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attitude of demeanour.  
4 Distinct feelings of sadness/hopelessness, which may be spontaneously divulged,  but depressed mood minimally 
affects behaviour/social functioning. Can usually be cheered up. 
5 Distinct depressed mood associated with obvious sadness, pessimism, loss of social interest, psychomotor 
retardation, and some interference in appetite or sleep. Patient cannot easily be cheered up. 
6 Markedly depressed mood, misery, hopelessness, worthlessness, occasional crying. Major interference with 
appetite and/or sleep as well as normal motor and social functions. Signs of possible self-neglect. 
7 Depressive feelings seriously interfere in most major functions. Frequent crying, pronounced somatic symptoms, 
impaired concentration, self neglect, social disinterest, possible depressive or nihilistic delusions. Possible suicidal 
thoughts/actions. 
 
 
G12 Lack of judgement and insight (impaired awareness/understanding of one’s psychiatric condition and 
life  situation. Denial of the need for treatment, inability to recognise psychiatric symptoms, unrealistic short-
term  and long-term planning) 
Do you generally feel that you are in need of help and treatment from people such as Dr XXX 
(patients doctor) 
Do you feel you have a psychiatric illness or do you feel you have had one in the past? 
         If YES 
What is it? 
How serious do you feel it is on a scale of 1 to 10 (10 being the most serious it could be) 
Where do you see yourself/what would you hope to be doing in 1 years time/5 years time? 
 
1 The definition doesn’t apply 
2 Questionable pathology – patient may be upper extreme of normal limits 
3 Recognises psychiatric disorder but underestimates seriousness, implications for treatment or the importance of 
taking measures to avoid relapse. Future planning may be poorly conceived 
4 Vague/shallow recognition of illness. Fluctuations in acknowledgement of being ill or little awareness of major 
symptoms that are present such as delusions, disorganised thinking, suspiciousness and social withdrawal. May 
rationalise treatment to relieve lesser symptoms e.g. anxiety, poor sleep etc. 
5 Acknowledge past but not present disorder. If challenged, may concede the presence of some unrelated or 
insignificant symptoms which tend to be explained away by gross misinterpretation or delusional thinking. Need for 
treatment us unrecognised. 
6 Denies ever having a psychiatric disorder, Patient disavows the presence of any psychiatric symptoms in the past 
or present, and denies the need for treatment/hospitalisation. 
7 Emphatic denial of past and present illness with current hospitalisation/treatment given a delusional interpretation 
(eg. As a punishment for misdeeds, or persecution by tormentors) The patient may refuse to cooperate with 
therapists, medication or other aspects of treatment. 
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 P1 Delusions (beliefs that are unfounded, unrealistic, and idiosyncratic/peculiar) 
 
Delusions of reference 
Do you feel at times that others make references or say things with a double meaning? 
Do you see messages for yourself in the newspaper or on TV? 
Do you occasionally feel that some events or incidents have a special meaning particularly for you? 
Delusional misinterpretation 
Do you occasionally see a secret message in the way objects are arranged or in their 
labelling or colour or in the way things happen? 
Quotation of ideas 
Do you find that something you have previously thought or discussed is quoted on TV or in 
the newspapers, or used in some other way to indicate a reference to you? 
Familiar people impersonated 
Do you feel that the appearance of any people you know well has changed in ways that 
suggest that someone might be impersonating them? 
Delusions of persecution 
 Does anyone seem to be trying to harm you? 
If YES are they particularly singling you out? 
How do you experience this? 
Does there seem to be a plot or a conspiracy behind it? 
 How do you recognise it? 
 
1 The definition doesn’t apply 
2 Questionable – patient may be upper extreme of normal limits 
3 1 or 2 delusions that are vague, uncrystallised and not tenaciously held. Delusions do not interfere with thinking, 
social relations or behaviour  
4 Presence of either a kaleidoscopic array of poorly formed, unstable delusions or a few well formed delusions that 
occasionally interfere with patients thinking, social relations or behaviour. 
5 Numerous well formed delusions that are tenaciously held and occasionally interfere with patients thinking, social 
relations or behaviour 
6 Stable set of delusions that clearly interfere with patients thinking, social relations and behaviour 
7 Highly systemised or very numerous stable delusions, that dominate major facets of patients life. Often results in 
inappropriate/irresponsible action that may jeopardise safety of patient or others. 
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P5 Grandiosity (exaggerated self-opinion and unrealistic convictions of superiority, including delusions of 
extraordinary abilities, wealth, knowledge, fame, power and moral righteousness) 
How do you feel you compare to the average person? Better or worse? 
Do you have talents/abilities/special or unusual powers that most people don’t have? 
 For example, do you ever feel you read another person’s mind? 
Do you consider yourself wealthy? Famous? Have you ever appeared on television, radio, movies 
or stage? 
Do you rate higher in terms of your moral standards?  
 Does this make you special in some respect? 
Do you have a special mission in life?  
 How did this come about? 
 Are you a religious person? 
 What is your relationship with god? 
 Are you closer to god than others are? 
 
1 The definition doesn’t apply 
2 Questionable – patient may be upper extreme of normal limits 
3 Some expansiveness or boastfulness is evident, but without clear-cut grandiose delusions. 
4 Feels Distinctly and unrealistically superior to others. Some poorly formed delusions about special status/abilities 
may be present but not acted upon. 
5 Clear-cut delusions concerning remarkable abilities/status /power that influence patients attitude but not behaviour 
6 Clear cut delusions of remarkable superiority involving more than 1 parameter (wealth, fame, knowledge) are 
expressed, notably  influence interactions, and may be acted upon 
7 Thinking, interactions and behaviour are dominated by multiple delusions of amazing 
ability/wealth/knowledge/fame/power/moral stature which may take on a bizarre quality. 
 
 
P6 Suspiciousness/Persecution (unrealistic/exaggerated ideas of persecution are shown, as reflected in 
guardedness, a distrustful attitude, suspicious hypervigilance, or delusions that others mean one harm 
How do you feel you get along with other people? 
Do you like other people? Dislike people?  
 If patient dislikes people : 
 Do you get particularly annoyed with people?  
 Afraid of people? Why? 
Do you feel most people like you? Dislike you? Why? 
Do you trust most people you know? 
 Are there some whom you distrust? Who? Why? 
Do you ever feel some people talk about you behind your back?  
 What do you think they say? Why? 
Do you ever feel some people spy on you/plot against you/attempt to harm you/attempt to 
kill you? 
 What is the evidence for this?  
 Who is behind all this?  
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 Why does it happen? 
 
1 The definition doesn’t apply 
2 Questionable – patient may be upper extreme of normal limits 
3 Presents a guarded or openly distrustful attitude, but thoughts/interactions/behaviour are minimally affected. 
4 Distrustfulness is clearly evident, intrudes on interview and his/her behaviour, but there is no evidence of 
persecutory delusions. Or loosely formed persecutory delusions which do not seem to affect patients’ 
attitude/interpersonal relations. 
5 Patient shows marked distrustfulness, leading to major disruptions in interpersonal relations. Or clear cut delusions 
that have limited impact on his/her interpersonal relations and behaviour. 
6 Clear cut pervasive delusions of persecution which may be systematised and that significantly interfere in patients 
interpersonal relations 
7 A network of systemised persecutory delusions dominates the patients thinking, social relations and behaviour 
 
 
P7 Hostility (verbal & non-verbal expressions of anger and resentment, including sarcasm, passive-
aggressive behaviour, verbal abuse and assaultiveness 
 How have you been getting along with people lately? (family, co-workers etc) 
If patient hasn’t been getting on well with people – why? 
 Have you been irritable or grumpy lately? 
If YES, does this lead to arguments with others even about minor issues, which normally wouldn’t 
bother you? 
 Were you ever so irritable that you would shout out at people or start arguments or 
fights? 
 
1 The definition doesn’t apply 
2 Questionable – patient may be upper extreme of normal limits 
3 Indirect or restrained communication of anger (e.g. sarcasm, disrespect, hostile expressions or occasional 
irritability) 
4 Patient presents an overtly hostile attitude showing frequent irritability and direct expression of anger or resentment 
5 Highly irritable and occasionally verbally abusive or threatening 
6 Uncooperativeness and verbal abuse or threats notably influence the interview and seriously impact upon patients 
social relations. Patient may be violent and destructive but not physically assaultive towards others 
7 Marked anger results in extreme uncooperativeness precluding other interactions, or in episodes of physical assault 
towards others. 
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P3 Hallucinatory behaviour (verbal report or behaviour indicate perceptions that are not generated by 
external stimuli. May be auditory, visual, olfactory or somatic) 
Do you ever have strange experiences/hear strange noises or sometimes hear things that 
others don’t hear? 
Do you sometimes receive personal communications from the radio or television? 
Can you sometimes hear your thoughts aloud in your head? Do they sound like voices? 
If patient hears voices:  
How many are there?  
Do they speak to you, comment about you, or speak to each other? 
What do the voices say?  
Are they good or bad voices?  
Are you afraid of them? 
Do the voices tell you what to do? Give you direct orders? 
 Do you obey the voices’ commands? Must you? 
Do ordinary things ever appear strange or distorted or do you ever have visions or see 
things others don’t? 
If YES,  
How often? 
How clear are these visions? 
 Do the visions occur together with the voices or separately? 
 Do you ever smell things that others don’t? 
 Do you ever get strange sensations from within your body or feel something strange inside you? 
If patient reports voices or visions, explore further with: 
 What do you make of these voices / visions etc…? 
 How did they come about? 
 Are they a problem?  
1 The definition doesn’t apply 
2 Questionable pathology; may be at the upper extreme of normal limits 
3 1 or 2 clearly formed but infrequent hallucinations or a number of vague abnormal perceptions which do not result 
in distortions of thinking or behaviour. 
4 Hallucinations occur frequently but not continuously, and the patients thinking and behaviour are affected only to a 
minor extent. 
5 Hallucinations are frequent, may involve more than one sensory modality, and tend to distort thinking and/or disrupt 
behaviour. Patient may have a delusional interpretation of these experiences and respond to them emotionally and, 
on occasion, verbally as well. 
6 Hallucinations are present almost continuously, causing major disruption of thinking and behaviour. Patient treats 
these as real perceptions, and functioning is impeded by frequent emotional and verbal responses to them. 
7 Patients is almost totally preoccupied with hallucinations, which virtually dominate thinking and behaviour. 
Hallucinations are provided a rigid delusional interpretation and provoke verbal and behavioural responses, 
including obedience to command hallucinations. 
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 G13 Disturbance of volition (disturbance in wilful initiation, sustenance, and control of one’s thoughts, 
behaviour, movements and speech.  
Do you find it difficult to make decisions in your day to day life? 
 If YES, has this occurred in the last week?  
 Example? 
Do you find your behaviour is sometimes aimless and disconnected, so that your daily 
routine is chaotic, because you are unable to plan your actions properly? 
 If answer YES to any of these, explore further, ask for an example/why do you think this is etc. 
 
1 The definition doesn’t apply 
2 Questionable pathology – patient may be upper extreme of normal limits 
3 Some evidence of indecisiveness in conversation and thinking that may impede verbal and cognitive processes to a 
minor extent 
4 The patient is often ambivalent and shows clear difficulty reaching decisions. Conversation may be marred by 
thinking alteration, and consequently, his or her verbal and cognitive functioning are clearly impaired. 
5 Disturbance of volition interferes in behaviour and thinking. Pronounced indecision that impedes the initiation and 
continuation of social and motor activities, and which may be evidenced in halting speech 
6 Execution of simple automatic motor functions (e.g. dressing/grooming) is interfered with, and speech is markedly 
affected. 
7 Almost complete failure of volition is manifested by severe inhibition of movement and speech.  
 
 
G10 Disorientation (lack of awareness of one’s relationship to one’s surroundings, including persons, 
places, and time that may be due to confusion or withdrawal) 
Do you know what day it is today? 
Month? 
Year? 
Season? 
Date? 
Where we are? 
 
1 The definition doesn’t apply 
2 Questionable pathology – patient may be upper extreme of normal limits 
3 General orientation is adequate but patient may have difficult with specifics, for example knows their location but 
not street address, knows hospital staff names but not their function, knows month but confuses day of the week. 
There may be narrowing of interest evidenced by familiarity with immediate but not extended milieu (ie identifies the 
staff but not Prime Minister etc). 
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4 Only partial success in recognising persons, places and time. For example, patient knows they are in a hospital but 
it’s name, knows name of primary therapist but not many other direct care worker, knows year but not sure of 
month. 
5 Considerable failure in recognising persons, places and time, for example has only vague notion of their 
whereabouts, and unfamiliar with most people in their milieu. May know year but not month, day or season.  
6 Marked failure in recognising persons, places and time. (no knowledge of whereabouts, confuses date, can only 
name 1 or 2 individuals in current life. 
7 Complete disorientation with regard to persons, places and time. Gross confusion or total ignorance about location, 
the current year, and even the most familiar people, such as parents, spouse, therapist etc.  
 
 
N5 Difficulty in abstract thinking (impairment in abstract-symbolic thinking, as demonstrated by difficulty 
in classification, forming generalisations, and moving beyond concrete or egocentric thinking in problem 
solving tasks) 
 
(See appendix I for list) 
1 The definition doesn’t apply 
2 Questionable – patient may be upper extreme of normal limits 
3 Tends to give literal or personalised interpretations to the more difficult proverbs, and some problems with concepts 
that are fairly abstract or remotely related 
4 Often utilises concrete mode. Difficulty with most proverbs and some categories. Tends to be distracted by 
functional aspects and salient features. 
5 Patient deals primarily in concrete mode, exhibiting difficulty with most proverbs and many categories. 
6 Unable to grasp abstract meaning of proverbs or figurative expressions and can formulate classifications for only 
the most simple of similarities. Thinking is either vacuous or locked into functional aspects, salient features, and 
idiosyncratic interpretations. 
7 Only uses concrete thinking modes. No comprehension of proverbs, common metaphors or similes and simple 
categories. Event salient and functional attributes do not serve as a basis for classification. This rating may apply to 
those who cannot interact even minimally with the interviewer due to marked cognitive impairment.  
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G9 Unusual thought content (thinking is characterised by strange or bizarre ideas, ranging from those 
that are remote/atypical to those that are distorted and absurd) 
 
Basis for rating: Thought content expressed during the course of the interview.  
 
1 The definition doesn’t apply 
2 Questionable pathology; patient may be upper extreme of normal limits 
3 Thought content is somewhat peculiar or idiosyncratic, or familiar ideas are framed in an odd context.  
4 Ideas are frequently distorted and occasionally seem quite bizarre.  
5 Patient expresses many strange and fantastic thoughts (eg. Being adopted son of a king, being an escapee from 
death row) or some which are patently absurd (eg. Having hundreds of children, receiving radio messages from 
space via a tooth filling). 
6 Patient expresses many illogical or absurd ideas or some which have a distinctly bizarre quality (eg having 3 heads, 
being a visitor from another planet). 
7 Thinking is replete with absurd, bizarre and grotesque ideas. 
 
N3 Poor rapport (lack of interpersonal empathy, openness in conversation, and a sense of closeness, 
interest, or involvement with the interviewer. This is evidenced by interpersonal distancing and reduced 
verbal and nonverbal communication)  
 
Interpersonal behaviour during the course of interview. 
1 The definition doesn’t apply 
2 Questionable pathology; patient may be upper extreme of normal limits 
3 Conversation is characterised by a stilted, strained, or artificial tone. It may lack emotional depth or tend to remain 
on an impersonal, intellectual plane.  
4 Patient typically is aloof, with interpersonal distance quite evident. Patient may answer questions mechanically, act 
bored, or express disinterest.  
5 Disinvolvement is obvious and clearly impedes the productivity of the interview. Patient may tend to avoid eye or 
face contact. 
6 Patient is highly indifferent, with marked interpersonal distance. Answers are perfunctory, and there is little 
nonverbal evidence of involvement. Eye and face contact are frequently avoided. 
7 Patient is totally uninvolved with the interviewer. Patient appears to be completely indifferent and consistently 
avoids verbal and nonverbal interactions during the interview. 
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 N2 Emotional withdrawal (lack of interest in, involvement with and affective commitment to life events)  
 
Observation of interpersonal behaviour during the course of the interview. 
1 The definition doesn’t apply 
2 Questionable pathology; patient may be upper extreme of normal limits 
3 Usually lacks initiative and occasionally may show deficient interest in surrounding events.  
4 Patient is generally distanced emotionally from the milieu and its challenges but, with encouragement, can be 
engaged. 
5 Patient is clearly deattached emotionally from persons and events in the milieu, resisting all efforts at engagement. 
Patient appears distant, docile, and purposeless but can be involved in communication at least briefly and tends to 
personal needs, sometimes with assistance. 
6 Marked deficiency of interest and emotional commitment results in limited conversation with others and frequent 
neglect of personal functions, for which the patient requires supervision. 
7 Patient is almost totally withdrawn, uncommunicative, and neglectful of personal needs as a result of profound lack 
of interest and emotional commitment.  
 
 
N4 Passive/apathetic social withdrawal (diminished interest and initiative in social interactions due to 
passivity, apathy, anergy or avolition leading to reduced interpersonal involvements and neglect of daily 
living activities). Reports from others only. 
How do you spend your time these days? Do you prefer to be alone? 
Do you join in on activities with others? 
 (if not) Why not? 
Do you have many friends? 
 (If no) do you have any friends? 
Do you have any close friends?  
 How often do you see them? 
(if not) Why not? 
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1 The definition doesn’t apply 
2 Questionable pathology; patient may be upper extreme of normal limits 
3 Shows occasional interest in social activities but poor initiative. Usually engages with others only when approached 
first by them.  
4 Passively goes along with most social activities but in a disinterested or mechanical way. Tends to recede into the 
background. 
5 Passively participates in only a minority of activities and shows virtually no interest or initiative. Generally spends 
little time with others. 
6 Tends to be apathetic and isolated, participating very rarely in social activities and occasionally neglecting personal 
needs. Has very few spontaneous social contacts. 
7 Profoundly apathetic, socially isolated, and personally neglectful.  
 
 
G16  Active social avoidance (diminished social involvement associated with unwarranted fear, hostility or 
distrust).Reports from others only. 
 
1 The definition doesn’t apply 
2 Questionable pathology; patient may be upper extreme of normal limits 
3 Patient seems ill at ease in the presence of others and prefers to spend time alone, although she/he participates in 
social functions when required. 
4 The patient begrudgingly attends all or most social activities but may need to be persuaded or may terminate 
prematurely on account of anxiety, suspiciousness, or hostility.  
5 Patient fearfully and angrily keeps away from many social interactions despite others’ efforts to engage them. 
Tends to spend unstructured time alone. 
6 Patient participates in very few social activities because of fear, hostility or distrust. When approached, the patient 
shows a strong tendency to break off interactions, and generally tends to isolate themselves.  
7 Patient cannot be engaged in social activites because of pronounced fears, hostility, or persecutory delusions. 
Avoids all interactions and remains isolated from others. 
 
 
 
 
DOI: 10.3310/hta20110 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 11
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Priebe et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
67
P2 Conceptual disorganisation (Disorganised process of thinking characterised by disruption of goal-
directed sequencing, eg., circumstantiality, tangentiality, loose associations, non-sequiturs, thought 
block or gross illogicality.  
 
Basis for rating: Cognitive verbal processes observed during the course of interview. 
1 The definition doesn’t apply 
2 Questionable pathology; patient may be upper extreme of normal limits 
3 Thinking is circumstantial, tangential, or paralogical. There is some difficulty in directing thoughts toward a goal, 
and some loosening of associations may be evidenced under pressure.  
4 Able to focus thoughts when communications are brief and structured, but becomes loose or irrelevant when 
dealing with more complex communications or when under minimal pressure. 
5 Generally has difficulty in organising thoughts, as evidenced by frequent irrelevancies, disconnectedness, or 
loosening of associations, even when not under pressure. 
6 Thinking is seriously derailed and internally inconsistent, resulting in gross irrelevancies and disruption of thought 
processes, which can occur almost constantly. 
7 Thoughts are disrupted to the point where the patient is incoherent. There is marked loosening of associations, 
which results in total failure of communication, eg., ‘word salad’, or mutism.  
 
 
G7 Motor retardation (Reduction in motor activity reflected by the slowing or lessening of movements and 
speech, diminished responsiveness to stimuli, and reduced body tone). 
 
Basis for rating: manifestations during the course of the interview 
1 The definition doesn’t apply 
2 Questionable pathology; patient may be upper extreme of normal limits 
3 Slight but noticeable diminution in rate of movements and speech; patient may be somewhat unproductive in 
conversation and gestures.  
4 Patient is clearly slow in movements, and speech may be characterised by poor productivity, including long 
response latency, extended pauses, or slow pace. 
5 A marked reduction in motor activity renders communication highly unproductive or delimits functioning in social 
and occupational situations. Patient can usually be found sitting or lying down. 
6 Movements are extremely slow, resulting in a minimum of activity and speech. Essentially the day is spent idly or 
lying down. 
7 Patient is almost completely immobile and virtually unresponsive to external stimuli. 
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 N6 Lack of spontaneity and flow of conversation (reduction in the normal flow of communication 
associated with apathy, avolition, defensiveness, or cognitive deficit. This is manifested by diminished fluidity and 
productivity of the verbal-interactional process.  
 
Rating based on cognitive-verbal processes observed during the course of the interview. 
1 The definition doesn’t apply 
2 Questionable pathology; patient may be upper extreme of normal limits 
3 Conversation shows little initiative. Patients answers tend to be brief and unembellished, requiring direct and 
leading questions by the interviewer. 
4 Conversation lacks free flow and appears uneven or halting. Leading questions are frequently needed to elicit 
adequate responses and proceed with conversation. 
5 Patient shows a marked lack of spontaneity and openness, replying to the interviewers questions with only one or 
two brief sentences.  
6 Patient’s responses are limited mainly to a few words or short phrases intended to avoid or curtail communication 
(eg ‘I don’t know’, ‘I’m not at liberty to say’). Conversation is seriously impaired as a result, and the interview is 
highly unproductive. 
7 Verbal output is restricted to, at most, an occasional utterance, making conversation not possible. 
 
N7 Stereotyped thinking (decreased fluidity, spontaneity, and flexibility of thinking, as evidenced in rigid, 
repetitious, or barren thought content) 
 
Rated on cognitive verbal processes observed during the interview. 
1 The definition doesn’t apply 
2 Questionable pathology; patient may be upper extreme of normal limits 
3 Some rigidity shown in attitudes or beliefs. Patient may refuse to consider alternative positions or have difficulty in 
shifting from one idea to another. 
4 Conversation revolves around a recurrent theme, resulting in difficulty in shifting to a new topic. 
5 Thinking is rigid and repetitious to the point that, despite the interviewers efforts, conversation is limited to only two 
or three dominating topics.  
6 Uncontrolled repetition of demands, statements, ideas, or questions which severely impairs conversation. 
7 Thinking, behaviour, and conversation are dominated by constant repetition of fixed ideas or limited phrases, 
leading to gross rigidity, inappropriateness and restrictiveness of patients communication. 
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N1 Blunted affect (diminished emotional responsiveness characterised by a reduction in facial expression, 
modulation of feelings, and communicative gestures).  
 
Observed manifestations of affective tone and emotional responsiveness during the course of the interview. 
1 The definition doesn’t apply 
2 Questionable pathology; patient may be upper extreme of normal limits 
3 Changes in facial expression and communicative gestures seem to be stilted, forced, artificial, or lacking in 
modulation. 
4 Reduced range of facial expression and few expressive gestures result in a dull appearance.  
5 Affect is generally ‘flat’, with only occasional changes in facial expression and paucity of communicative gestures.  
6 Marked flatness and deficiency of emotions exhibited most of the time. There may be unmodulated extreme 
affective discharges, such as excitement, rage, or inappropriate uncontrolled laughter. 
7 Changes in facial expression and evidence of communicative gestures are virtually absent. Patient seems 
constantly to show a barren or ‘wooden’ expression.  
 
P4 Excitement (hyperactivity is reflected in accelerated motor behaviour, heightened responsivity to 
stimuli, hypervigilance, or excessive mood lability.)  
 
Rating based upon behavioural manifestations during the course of the interview. 
1 The definition doesn’t apply 
2 Questionable pathology; patient may be upper extreme of normal limits 
3 Tends to be slightly agitated, hypervigilant or mildly overaroused throughout the interview, but without distinct 
episodes of excitement or marked mood liability. Speech may be slightly pressured. 
4 Agitation or overarousal is clearly evident throughout the interview, affecting speech and general mobility or 
episodic outbursts occur sporadically.  
5 Significant hyperactivity or frequent outbursts of motor activity are observed, making it difficult for the patient to sit 
longer than several minutes at any given time. 
6 Marked excitement dominates the interview, delimits attention and to some extent affects personal functions such 
as eating or sleeping. 
7 Marked excitement seriously interferes in eating and sleeping and makes interpersonal interactions virtually 
impossible. Acceleration of speech and motor activity may result in incoherence and exhaustion.  
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G5 Mannerisms and posturing (unnatural movements or posture are shown as characterised by an 
awkward, stilted, disorganised, or bizarre appearance). 
 
Ratings based on the observation of physical manifestations during the course of interview. 
1 The definition doesn’t apply 
2 Questionable pathology; patient may be upper extreme of normal limits 
3 Slight awkwardness in movements or minor rigidity of posture. 
4 Movements are notably awkward or disjointed, or an unnatural posture is maintained for brief periods. 
5 Occasional bizarre rituals or contorted posture are observed, or an abnormal position is sustained for extended 
periods. 
6 Frequent repetition of bizarre rituals, mannerisms, or stereotyped movements, or a contorted posture is sustained 
for extended periods. 
7 Functioning is seriously impaired by virtually constant involvement in ritualistic, manneristic, or stereotyped 
movements or by an unnatural fixed posture which is maintained most of the time. 
 
 
G14  Poor impulse control (there is disordered regulation and control when acting on inner urges, resulting 
in sudden, unmodulated, arbitrary, or misdirected discharge of tension and emotions without concern 
about the consequences.  
Basis for rating: Behaviour during the course of the interview or else otherwise reported. 
1 The definition doesn’t apply 
2 Questionable pathology; patient may be upper extreme of normal limits 
3 Patient tends to be easily angered and frustrated when facing stress or denied gratification but rarely acts on 
impulse.  
4 Patient get angered and verbally aggressive with minimal provocation. May be occasionally threatening, 
destructive, or have one or two episodes involving physical confrontation or a minor brawl. 
5 Patient  exhibits repeated impulsive episodes involving verbal abuse, destruction of property, or physical threats. 
There may be one or two episodes involving serious assault, for which the patient requires isolation, physical 
restraint, or sedation. 
6 Patient frequently is impulsively aggressive, threatening, demanding, and destructive, without any apparent 
consideration of consequences. Shows assaultive behaviour and may also be sexually offensive and possibly 
respond behaviourally to hallucinatory commands. 
7 Patient exhibits homicidal attacks, sexual assaults, repeated brutality, or self-destructive behaviour. Requires 
constant direct supervision or external constraints because of inability to control dangerous impulses. 
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G4 Tension (There are overt physical manifestations of fear, anxiety, and agitation, such as stiffness, tremors, 
profuse sweating, and restlessness). 
 
Based upon verbal report attesting to anxiety, and thereupon the severity of physical manifestations of tension 
observed during the interview. 
1 The definition doesn’t apply 
2 Questionable pathology; patient may be upper extreme of normal limits 
3 Posture and movements indicate slight apprehensiveness, such as minor rigidity, occasional restlessness, shifting 
of position, or rapid hand tremor. 
4 A clearly nervous appearance emerges from various manifestations, such as fidgety behaviour, obvious hand 
tremor, excessive perspiration, or nervous mannerisms. 
5 Pronounced tension is evidenced by numerous manifestations, such as nervous shaking, profuse sweating, and 
restlessness, but conduct in the interview is not significantly affected.   
6 Pronounced tension to the point that interpersonal interactions are disrupted. The patient, for example, may be 
constantly fidgeting, unable to sit still for long, or show hyperventilation.  
7 Marked tension is manifested by signs of panic or gross motor acceleration, such as rapid restless pacing an 
inability to remain seated for longer than a minute, which makes sustained conversation not possible. 
 
G8 Uncooperativeness (active refusal to comply with the will of significant others, including the 
interviewer, hospital staff, or family, perhaps associated with distrust, defensiveness, stubbornness, 
negativism, rejection of authority, hostility, or belligerence.  
Basis for rating: Interpersonal behaviour observed during the course of the interview. 
1 The definition doesn’t apply 
2 Questionable pathology; patient may be upper extreme of normal limits 
3 Complies with an attitude of resentment, impatience, or sarcasm. May inoffensively object to sensitive probing 
during the interview. 
4 Occasional outright refusal to comply with normal social demands, such as making own bed, scheduled 
appointments etc. The patient may project a hostile, defensive, or negative attitude but usually can be worked with. 
5 Patient is frequently noncompliant with the demands of his/her milieu and may be characterised by others as an 
‘outcast’ or having a serious ‘attitude problem’. Uncooperativeness  is reflected in obvious defensiveness or 
irritability with the interviewer and may be unwilling to address many questions. 
6 Patient is highly uncooperative, negativistic, and possibly also belligerent. Refuses to comply with most social 
demands and may be unwilling to initiate or conclude the full interview. 
7 Active resistance seriously impact on virtually all major areas of functioning. Patient may refuse to join in any social 
activities, tend to personal hygiene, converse with family or staff, and participate even briefly in an interview. 
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G11  Poor attention (poor focussed alertness is manifested by poor concentration, distractibility from internal 
and external stimuli, and difficulty in harnessing, sustaining, or shifting focus to new stimuli.) 
 
Basis for rating: Manifestations during the course of the interview. 
1 The definition doesn’t apply 
2 Questionable pathology; patient may be upper extreme of normal limits 
3 Limited concentration evidenced by occasional vulnerability to distraction or faltering attention toward the end of the 
interview. 
4 Conversation is affected by the tendency to be easily distracted, difficulty in long sustaining concentration on a 
given topic, or problem shifting attention on to new topics. 
5 Conversation is seriously hampered by poor concentration, distractibility, and difficulty in shifting focus 
appropriately.  
6 Patients attention can be harnessed for only brief moments or with graet effort, due to marked distraction by 
internal or external stimuli. 
7 Attention is so disrupted that even brief conversation is not possible. 
 
G15  Preoccupation (there is an absorption with internally generated thoughts and feelings or with autistic 
experiences to the detriment of reality orientation and adaptive behaviour. 
 
Interpersonal behaviour reported during the course of the interview. 
1 The definition doesn’t apply 
2 Questionable pathology; patient may be upper extreme of normal limits 
3 Excessive involvement with personal needs or problems, such as that conversation veers back to ego-centric 
themes and there is diminished concern exhibited toward others. 
4 Patients occasionally appears self-absorbed, as if daydreaming or involved with internal experiences, which 
interferes with communication to a minor extent. 
5 Patient often appears to be engaged in autistic experiences, as evidenced by behaviours that significantly intrude 
on social and communicational functions, such as the presence of a vacant stare, muttering  or talking to oneself, or 
involvement with stereotyped motor patterns. 
6 Marked preoccupation with autistic experiences, which seriously delimits concentration, ability to converse, and 
orientation to the milieu. The patients frequently may be observed smiling, laughing, muttering, talking or shouting 
to oneself. 
7 Gross absorption with autistic experiences, which profoundly affects all major realms of behaviour. The patient 
constantly may be responding verbally and behaviourally to hallucinations and show little awareness of other 
people or the external milieu. 
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Questions for assessing Abstract thinking: 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
74
[Note: Romantic relationships can be rated in either Item 1 or Item 2 but NOT both. A spouse/ partner 
relationship in which the couple is living together should be assessed in Item 1. A dating/romantic 
relationship in which the couple is not living together should be assessed in Item 2.] 
 
Behavior 
 
Motivation & Interest in Closeness 
[NOTE: This section applies when not part of a close family or if available relatives could be contacted 
but person has chosen not to interact. If the person is not currently in a relationship with a live-in 
spouse/partner, interest in romantic relationships is assessed in Item 2.] 
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VERY INTERESTED in and highly values close family bonds as one of the most 
 important parts of life. Strongly desires and is highly motivated to be in contact with family. Regularly 
initiates and persists in interactions with family and actively engages in these interactions; good and 
bad times are openly discussed. Well within normal limits. 
GENERALLY INTERESTED in and values close family bonds though response 
suggests some minor or questionable reduction. Generally desires and is motivated to maintain 
contact with family. Has a close relationship with family member(s) in which good and bad times can 
be discussed. Mild deficit in initiating and persisting in regular interactions with family – generally 
actively engaged when interactions occur. 
SOMEWHAT INTERESTED in family relationships and considers them  
somewhat important. May occasionally miss close connections with family but is only somewhat 
motivated to seek out interaction with family. Notable deficit in initiating and persistently engaging in 
interactions; discussion of good and bad times is limited. Interactions with family members may occur 
but are largely superficial and participation is best characterized as “going through the motions”; 
interactions are more likely initiated by family  with mostly passive involvement of the person. 
LITTLE INTEREST in family relationships (could “take it or leave it”) 
and does not describe family bonds as important. Describes hardly any motivation and  minimal 
effort to have close family relationships. Rarely has discussion of good and bad times  with family 
members. Contact and engagement with family is superficial and passive with  almost all initiation 
and efforts to engage coming from others. 
NO INTEREST in family relationships and does not consider them at all important. 
Prefers to be alone and is not at all motivated to be with family. If person does see family, it is done so 
grudgingly, passively and with no interest. 
 
• 
 
Behavior 
• What steps did you take to see or contact your [friends/partner/dates] in the past week? 
• When you were with your [friends/partner/dates], who decided what you would do? 
• When you spoke with your [friends/partner/dates], who started the conversation? Did you? 
• Did you ever find that you quickly wanted to end your interaction with your [friends/partner/dates]? 
Did you want them to last longer? 
 
Motivation & Interest in Closeness 
• (partner/dates) 
(partner/dates)
(partner/dates) 
(partner/dates)
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• 
VERY INTERESTED in and highly values friend/romantic relationships as one of 
the most important parts of life. Strongly desires and is very motivated to engage in friendships. 
Regularly initiates and persists in interactions with friends/partner and actively engages in these 
interactions; good and bad times are openly discussed. Well within normal limits. 
GENERALLY INTERESTED in and values friend/romantic relationships though 
response suggests some minor or questionable reduction. Generally desires and is motivated to 
engage in friendships. Has friendships/relationship in which good and bad times can be discussed 
though this may be less consistent. Mild deficit in initiating or persistently engaging during interactions 
with friends/partner. If no friends/relationship, misses friend/romantic relationships, is motivated to 
have friends/relationship, and makes efforts to seek out friends/relationship. 
SOMEWHAT INTERESTED in friend/romantic relationships and considers them 
somewhat important. May occasionally miss close connections with friends/partner and is somewhat 
motivated to have friends/partner. Notable deficit in initiating and persistently engaging in interactions; 
discussion of good and bad times is limited. Interactions with friends/romantic partner may occur but 
are largely superficial and participation is best characterized as “going through the motions”; 
interactions are initiated by others with mostly passive involvement of the person. If no friend/romantic 
relationships, is only somewhat motivated to have friends/partner and rarely if ever seeks out 
friends/partner. 
LITTLE INTEREST in friend/romantic relationships (could “take it or 
leave it”) and does not describe friends/partner as important. Describes hardly any motivation to have 
friendships, and would just as soon be alone. Contact and engagement with others is superficial and 
passive with almost all initiation and efforts to engage coming from others. 
NO INTEREST in friend/romantic relationships and does not consider them at all 
important. Prefers to be alone and is not at all motivated to have friends/partner. 
[NOTE: Ratings are based on that pleasurable activity with other 
people is experienced. When there are reports of several different activities occurring, clarify if these 
happened on same or different days.] 
 
• (PAUSE) 
• (PAUSE) 
• (PAUSE) 
• ? (PAUSE) 
• 
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• 
• [If many (i.e., 5 or 6) days mentioned or if not clear which days of week interactions were enjoyed] 
: Pleasure experienced daily. 
: Pleasure experienced 5-6 days. 
: Pleasure experienced 3-4 days. 
: Pleasure experienced 1-2 days. 
: No pleasure reported 
 
 
[NOTE: Ratings are based on total regardless of 
days on which they are expected to occur]. 
 
• 
• 
Expecting MANY (7 or more) pleasurable experiences. 
Expecting enjoyment from SEVERAL (5-6) pleasurable experiences. 
Expecting enjoyment from a FEW (3-4) pleasurable experiences. 
Expecting a COUPLE (1-2) pleasurable experiences. 
Expecting NO pleasurable experiences. 
 
 
• 
 
Behavior 
• 
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
78
 
Motivation 
• 
• 
Person is VERY MOTIVATED to seek out work or school, or new opportunities in 
work or school; initiates and persists in work, school, or job-seeking on a regular basis. Well within 
normal limits. 
Person is GENERALLY MOTIVATED to seek out work or school or new opportunities 
in work or school; a mild deficit in initiating and persisting; may report instances of initiating, but with 
moderate persistence. 
Person is SOMEWHAT MOTIVATED to seek out work or school or new 
opportunities in work or school; notable deficit in initiating; may have initiated activities, but needed 
reminders on multiple occasions, and/or not initiated any new activities, and/or not persisted for very 
long. 
Person is only SLIGHTLY MOTIVATED to seek out work or school or 
new opportunities in work or school; significant deficit in initiating; may have needed constant 
reminders, and/or initiated a few activities; did not persist for very long. 
Person is NOT AT ALL MOTIVATED to seek out work / school; nearly total lack of 
initiation and persistence in work, school, or job seeking. 
 
 
[NOTE: Ratings are based on total regardless of 
days on which they are expected to occur]. 
• 
• 
• 
• 
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Expecting MANY (7 or more) pleasurable experiences. 
Expecting enjoyment from SEVERAL (5-6) pleasurable experiences. 
: Expecting enjoyment from a FEW (3-4) pleasurable experiences. 
Expecting a COUPLE (1-2) pleasurable experiences. 
: Expecting NO pleasurable experiences. 
 
• 
Behavior 
• 
 
Motivation 
• 
• 
Person is VERY MOTIVATED to seek out hobbies and recreational activities; 
initiates and persists in hobbies and recreational activities on a regular basis, well within normal limits. 
Person is GENERALLY MOTIVATED to seek out hobbies and recreational activities; 
a mild deficit in initiating and persisting; may report initiating hobbies, but with moderate persistence. 
Person is SOMEWHAT MOTIVATED to seek out hobbies and recreational 
activities; notable deficit in initiating; may have initiated some activities and/or not persisted for very 
long. Others were somewhat more likely to initiate hobbies or activities. 
Person is only SLIGHTLY MOTIVATED to seek out hobbies and 
recreational activities; significant deficit in initiating and persisting; may have initiated a few activities 
and not persisted for very long. Others were much more likely to initiate hobbies or prompt initiation. 
Person is NOT AT ALL MOTIVATED to seek out hobbies and recreational 
activities; nearly total lack of initiation and persistence in hobbies or recreational activities. 
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[NOTE: Rating is based on both of pleasurable activities and that these 
are experienced. When there are reports of several different activities occurring, need to clarify if 
these happened on same or different days.] 
 
At least A FEW (3) different types of pleasurable experiences, experienced daily. 
At least A FEW (3) different types of pleasurable experiences, experienced more 
days than not. 
1 or 2 different types of pleasurable experiences, experienced more days than 
not. 
1 type of pleasurable experience, experienced on just a few days. 
No pleasurable experiences. 
 
 
[NOTE: Ratings are based on total regardless 
ofdays on which they are expected to occur] 
• 
Expecting MANY (7 or more) pleasurable experiences. 
Expecting enjoyment from SEVERAL (5-6) pleasurable experiences. 
Expecting enjoyment from a FEW (3-4) pleasurable experiences. 
Expecting a COUPLE (1-2) pleasurable experiences. 
Expecting NO pleasurable experiences. 
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When making the facial expression rating, consider facial movements across all parts of the face, 
including in the eyes (e.g., raised brows when surprised), mouth (smiling or grimacing), and mid-face 
(e.g., wrinkled nose when disgusted). 
 
WITHIN NORMAL LIMITS; frequent expressions throughout the interview. 
MILD DECREASE in the frequency of facial expressions, with limited facial 
expressions during a few parts of the interview. 
NOTABLE DECREASE in the frequency of facial expressions, with diminished 
facial expressions during several parts of the interview. 
SIGNIFICANT LACK of facial expressions, with only a few changes in 
facial expression throughout most of the interview. 
NEARLY TOTAL LACK of facial expressions throughout the interview. 
 
 
This item refers to prosodic features of the voice. This item reflects changes in tone during the course 
of speech. Speech rate, amount, or content of speech is not assessed. 
 
 
WITHIN NORMAL LIMITS. Normal variation in vocal intonation across interview. 
Speech is expressive and animated. 
MILD DECREASE in vocal intonation. Variation in intonation occurs with a limited 
intonation during a few parts of the interview. 
NOTABLE DECREASE in vocal intonation. Diminished intonation during several 
parts of the interview. Much of speech is lacking variability in intonation but prosodic changes occur in 
several parts of the interview. 
SIGNIFICANT LACK of vocal intonation with only a few changes in 
intonation throughout most of the interview. Most of speech is flat and lacking variability, only isolated 
instance of prosodic change. 
NEARLY TOTAL LACK OF change in vocal intonation with characteristic flat or 
monotone speech throughout the interview. 
 
Expressive gestures are used to emphasize what is communicated verbally through gestures made 
with the hands, head (nodding), shoulders (shrugging), and trunk (leaning forward, leaning back). 
WITHIN NORMAL LIMITS; uses frequent gestures throughout the interview. 
MILD DECREASE in the frequency of expressive gestures, with limited gestures in a 
few parts of the interview. 
NOTABLE DECREASE in the frequency of expressive gestures, with lack of 
gestures during several parts of the interview. 
SIGNIFICANT LACK of expressive gestures, with only a few gestures 
throughout most of the interview. 
NEARLY TOTAL LACK of expressive gestures. 
This item refers to the quantity of words spoken. Other speech abnormalities, such as disorganization, 
neologisms, or psychotic content are not rated here. For instance, a disorganized person may 
produce a large quantity of speech and have a low (normal) score on this item. 
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NORMAL AMOUNT of speech throughout the interview. Replies provide 
sufficient information with frequent spontaneous elaboration. 
MILD DECREASE in the quantity of speech, with brief responses during a few parts 
of the interview. 
NOTABLE DECREASE in speech output, with brief responses during several 
parts of the interview. 
SIGNIFICANT LACK of speech, with very brief answers (only several 
words) in responses throughout most of the interview. 
All or nearly all replies are one or two words throughout the entire interview. 
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l=White    5=Indian 
2=Black Caribbean   6=Pakistani                             
3=Black African        7=Bangladeshi                     
4=Black other    8=Chinese 
9=Other                                            
Use ICD 10    
Section 2
In a first interview, ask all questions 1 to 9. In a repeat interview, ask first, whether there have been any 
changes in the respondent's circumstances as assessed in Section 2. If the answer is yes, complete questions 
1 to 9. If the answer is no, go straight to Section 3.
 l=In paid employment    4=Unemployed  
2=In sheltered employment    5=Retired  
3=Training/education is main occupation  6=Other                                                                      
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             l=Live alone   4=With child/children under 18  
  2=With partner    5= With child/children over 18 
3=With parents   6=Other (please specify)     _____________________ 
 
01=House/flat (owner occupied)  06=Sheltered housing  
02=House/flat (Housing association)   07=Residential home  
03=House/flat (private rent)    09=Hospital ward  
04=Boarding out (incl. B+B)   10=No fixed abode                                                                       
05=Hostel, supported/group home  
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ACTIVITY NUMBER OF TIMES AMOUNT OF TIME 
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A. Community Health Care Services 
csriAa 
csriAb 
 
B Primary care nurse 
csriAc 
csriAd 
csriAe 
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 Neurology 
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(If you take more than 6 drugs, please record the details on the back of this form) 
 
E. Your Employment 
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Under each heading, please tick the ONE box that best describes your health 
TODAY  
 
 
MOBILITY  
I have no problems in walking about       
I have slight problems in walking about      
I have moderate problems in walking about      
I have severe problems in walking about      
I am unable to walk about        
 
 
SELF-CARE  
I have no problems washing or dressing myself     
I have slight problems washing or dressing myself     
I have moderate problems washing or dressing myself    
I have severe problems washing or dressing myself    
I am unable to wash or dress myself      
 
 
USUAL ACTIVITIES (e.g. work, study, housework,  
family or leisure activities)  
I have no problems doing my usual activities     
I have slight problems doing my usual activities    
I have moderate problems doing my usual activities    
I have severe problems doing my usual activities     
I am unable to do my usual activities      
 
 
PAIN / DISCOMFORT  
I have no pain or discomfort        
I have slight pain or discomfort       
I have moderate pain or discomfort       
I have severe pain or discomfort       
I have extreme pain or discomfort       
 
 
ANXIETY / DEPRESSION  
I am not anxious or depressed       
I am slightly anxious or depressed       
I am moderately anxious or depressed      
I am severely anxious or depressed       
I am extremely anxious or depressed      
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